ORGANOMETALLICS

Synthesis and Reactivity of Ortho-Palladated 3-Phenylpropanamides. Insertion of CO, XyNC, and Alkynes into the Pd–C Bond. Synthesis of Seven- and Nine-Membered Palladacycles and Benzazepine- and Benzazonine-Based Heterocycles

Roberto Frutos-Pedreño, Pablo González-Herrero,* and José Vicente*

Grupo de Química Organometálica, Departamento de Química Inorgánica, Facultad de Química, Universidad de Murcia, Apdo. 4021, 30071 Murcia, Spain

Peter G. Jones

Institut für Anorganische und Analytische Chemie, Technische Universität Braunschweig, Postfach 3329, 38023 Braunschweig, Germany

Supporting Information

ABSTRACT: Aryl palladium complexes $[Pd\{C_6H_4(CH_2)_2C(O)-NRR')-2\}I(tmeda)]$ [NRR' = NH₂ (1a), NHMe (1b), NMe₂ (1c); tmeda = *N*,*N*,*N'*,*N'*-tetramethylethylenediamine] are prepared by oxidative addition of the corresponding 3-(2-iodophenyl)propanamides to "Pd(dba)₂" ([Pd₂(dba)₃]·dba; dba = dibenzylideneacetone) in the presence of tmeda. The cationic seven-membered palladacycles [Pd{ κ^2C ,*O*- $C_6H_4(CH_2)_2C(O)$ -NRR')-2}(tmeda)]TfO (2a-c) are obtained by reacting 1a-c with AgTfO. Neutral amidate complexes of the type [Pd{ κ^2C ,*N*-



 $C_6H_4(CH_2)_2C(O)NR)-2\}$ (tmeda)] [R = H (3a), Me (3b)] are obtained upon deprotonation of the amide function in 1a or 1b with KO'Bu. The reaction of 1a with CO at room temperature affords the stable acyl derivative [Pd{C(O)C₆H₄(CH₂)₂C-(O)NH₂-2}I(tmeda)] (4), while 2a gives Pd, (tmedaH)TfO, and 4,5-dihydro-2*H*-benzo[*c*]azepine-1,3-dione (5a). Compound 5a can also be obtained in high yield by treating the amidate complex 3a with CO, while a low yield of 2-methyl-4,5-dihydro-2*H*-benzo[*c*]azepine-1,3-dione (5b) was obtained from 3b under the same conditions. Complexes 1a-c react with 3 equiv of XyNC to give *trans*-[Pd{C(=NXy)C₆H₄(CH₂)₂C(O)NRR'-2}I(CNXy)₂] [NRR' = NH₂ (6a), NHMe (6b), NMe₂ (6c)]. By refluxing a CHCl₃ solution of 6a or 1a and XyNC in 1:1 molar ratio, mixtures of 1-(2,6-dimethylphenylimino)-1,2,4,5-tetrahydrobenzo[c]azepin-3-one (7a) and 2-(2-cyanoethyl)-*N*-(2,6-dimethylphenyl)benzamide (8a) are obtained. Complexes 2a-c react with alkynes in 1:1 molar ratio to give nine-membered palladacycles of the type [Pd{ $\kappa^2C,O-C(X)$ = $C(X)C_6H_4(CH_2)_2C(O)NRR'-2$ {tmeda)]TfO [NRR' = NH₂, X = Ph (9a), C₆H₄^mBu-4 (10a), C₆H₄Br-4 (11a), CO₂Me (12a); NRR' = NHMe, X = Ph (9b); NRR' = NMe₂, X = Ph (9c)]. The reaction of 2a with an excess of 3-hexyne gives the complex [Pd{ η^3 -C₆H₄(C₄Et₄)(CH₂)₂C(O)NH₂}{tmeda)]TfO (13), containing a spirocyclic ligand coordinated to Pd through a η^3 -allylic bond. The derivatives 9a, 10a and 11a react with CO at 50 °C in CHCl₃ to give colloidal Pd, (tmedaH)TfO, and the corresponding 6,7-disubstituted 1,2-dihydro-4*H*-benzo[*e*]azonine-3,5-diones (14, 15, 16), which result from a CO insertion/C-N reductive coupling sequence.

INTRODUCTION

Palladacycles are key intermediates in palladium-mediated cyclization reactions,^{1–3} which have become one of the most valuable tools for the synthesis of carbo- and heterocycles.^{4,5} The use of these reactions for the synthesis of medium-size rings (seven- to eleven-membered) through C–C or C– heteroatom coupling is of particular importance, because they form the basic structural motif in many compounds of biological or pharmacological significance⁶ and are difficult to prepare by other methods.⁷ However, the ring size of the majority of the isolated palladacycles described to date (five- or six-membered)^{3,8} is not appropriate for this purpose because

the organic ring generally has one fewer member. Palladacycles larger than six members are relatively uncommon and have been considered difficult to prepare because they tend to be unstable.^{1,9} However, methods for the enlargement of palladacycles are of utility, even when the product can not be isolated, because in many cases the desired organic ring is among the products of decomposition (see below).

Insertion reactions into the Pd–C bond are the best known method to enlarge the ring size of palladacycles. Thus, alkyne

Received: January 10, 2013 Published: February 20, 2013

monoinsertion reactions lead to a two-atom enlargement and have allowed the synthesis of seven-¹⁰⁻¹⁷ or, less frequently, eight-membered^{12,13,15,18-22} palladacycles. Alkyne di-insertions may lead to the expansion of the cyclopalladated ligand through the incorporation of a butadienyl fragment, giving nine-^{10,15,17,23,24} or ten-membered¹⁵ palladacycles that are generally stabilized by the π -coordination of one internal double bond. Similarly, palladacycle enlargements from six to eight members have been achieved by insertion of olefins into the Pd–C bond,^{25,26} while insertion of CO or isocyanides has allowed conversions from six to seven members.^{27,28} In addition, sequential insertion of one or two molecules of alkyne and CO or isocyanides have allowed conversions from six to nine²² or five to ten²⁴ members. Some of these enlarged palladacycles undergo depalladation reactions under certain conditions^{25,27} or are not isolable and decompose spontaneously^{22,26,27,29} to give heterocyclic compounds.

We have previously shown that ortho-palladated phenylacetamides of the type $[Pd{C_6H_4CH_2C(O)NRR'-2}I(tmeda)]$ and their cyclopalladated derivatives $[Pd{\kappa^2C_1O-C_6H_4CH_2C}-$ (O)NRR'-2 (tmeda)] TfO (NRR' = NH₂, NHMe, NMe₂) undergo C-N and/or C-O reductive couplings after the insertion of CO or XyNC into the Pd-C bond, leading to isoquinoline and/or isocoumarin derivatives under relatively mild conditions.³⁰ These reactions involve the deprotonation of NH₂ or NHMe groups (C–N couplings) or the α -CH₂ group (C-O couplings), which is effected by the tmeda ligand. In a subsequent study, we reported the synthesis of a series of eightmembered palladacycles of the type $[Pd\{\kappa^2 C, O-C(X)=C(X')-C(X')$ $C_6H_4CH_2C(O)NRR'-2\}$ (tmeda)]TfO (NRR' = NH₂, NHMe), obtained from alkyne monoinsertion reactions.²² The enlarged palladacycles also reacted with CO to give 3-benzazocine-2,4(1H,3H)-diones, resulting from an analogous CO insertion/ C-N reductive coupling sequence. With the main objective of exploring the limits of this methodology for the synthesis of heterocycles of a larger size, the present paper extends our reactivity studies to ortho-palladated 3-phenylpropanamides, from which seven-membered palladacycles can be obtained that, in turn, can be enlarged through the insertion of alkynes into the Pd-C bond to give nine-membered derivatives. Only a few examples of isolated nine-membered palladacycles have been previously reported that are not stabilized by the coordination of an internal double bond,^{24,31} and none of them were obtained from alkyne monoinsertion reactions. A systematic study of the reactivity of the new complexes toward CO or XyNC has allowed the synthesis of seven- and ninemembered heterocycles.

RESULTS AND DISCUSSION

Synthesis of Ortho-Palladated 3-Phenylpropanamides and Cyclometalated Derivatives. The aryl derivatives $[Pd\{C_6H_4(CH_2)_2C(O)NRR'-2\}I(tmeda)]$ $[NRR' = NH_2$ (1a), NHMe (1b), NMe₂ (1c); Scheme 1] were obtained in moderate yields by oxidative addition of the corresponding 3-(2-iodophenyl)propanamides to "Pd(dba)₂" ($[Pd_2(dba)_3]$ ·dba; dba = dibenzylideneacetone) in the presence of tmeda in CH₂Cl₂ at room temperature.

The reactions of complexes 1 with 1 equiv of AgTfO in acetone led to the precipitation of AgI and the formation of the corresponding cationic palladacycles [Pd{ $\kappa^2 C$,O-C₆H₄(CH₂)₂C(O)NRR'-2}(tmeda)]TfO (2a-c). These compounds turned out to be highly hygroscopic amorphous solids that could not be crystallized and were isolated by evaporating





the solvent. Their IR spectra in CH_2Cl_2 solution show the $\nu(C=O)$ band at 1646 (2a), 1608 (2b) or 1591 (2c) cm⁻¹; these frequencies are appreciably lower than those of the corresponding free amides (range 1670–1635 cm⁻¹), which confirms that the amide function is coordinated to the metal through the oxygen atom. Complexes 2a and 2c could not be obtained in analytically pure form because reprecipitations from acetone/Et₂O or CH_2Cl_2/Et_2O led to partial decomposition. However, they can be employed for the synthesis of other products (see below).

Deprotonation of the amide function in complexes 1a and 1b with excess KO'Bu in CH₂Cl₂ led in good yield to the neutral palladacycles [Pd{ $\kappa^2 C_r N \cdot C_6 H_4 (CH_2)_2 C(O)NR \cdot 2$ }(tmeda)] [R = H (3a), Me (3b)], which resulted from the displacement of the iodo ligand by the nitrogen of the anionic amidate group. Their solid-state IR spectra show the ν (C=O) band at 1551 (3a) or 1558 (3b) cm⁻¹, which is typical of *N*-coordinated amidato complexes.^{32,33} The attempts to deprotonate the α -CH₂ in the NMe₂ derivative 1c with KO'Bu were unsuccessful.

Reactions with CO. Arylpalladium complexes react with CO, often reversibly, to give acyl derivatives resulting from the insertion of this molecule into the Pd–C bond.^{3,20,30,34–37} This type of reaction has been extensively studied because it

constitutes a key step in palladium-catalyzed carbonylations.^{5,38} In many cases, acyl intermediates may further react with nucleophiles to give carbonyl-containing organic products. Treatment of complex 1a with CO in CH₂Cl₂ at room temperature afforded the expected insertion product [Pd{C- $(O)C_6H_4(CH_2)_2C(O)NH_2-2$ [(tmeda)] (4) in good yield (Scheme 1). In contrast to its homologue with ortho-palladated phenylacetamide,³⁰ complex 4 is remarkably stable, and we did not observe any decomposition to Pd(0) in solution under CO at room temperature, which implies that the possible C-N reductive coupling is much less favored. We then carried out the reactions of in situ generated solutions of palladacycles 2ac in CH_2Cl_2 with CO (1.4 bar) at room temperature, in the expectation that their cationic nature and cyclic structure would facilitate the insertion/reductive coupling sequence. When starting from the NH₂ derivative 2a, colloidal Pd, (tmedaH)-TfO, and 4,5-dihydro-2*H*-benzo[c]azepine-1,3-dione³⁹ (5a; 42% isolated yield) were obtained. However, the NHMe and NMe₂ derivatives (2b and 2c, respectively) were recovered unreacted. With hindsight, it is reasonable to assume that CO inserts reversibly into the Pd-C bond of 2b and 2c, but a subsequent C-N or C-O reductive coupling does not occur. The C-N coupling process may be difficult for 2b because of the lower acidity of the NH proton and the steric hindrance of the methyl group, while the anticipated C-O coupling processes from both 2b and 2c may not be possible because the α -CH₂ protons are not acidic enough, and thus the necessary deprotonation step does not take place.

The amidate complexes **3a** and **3b** were also treated with CO (1.4 bar) in CDCl₃ to test the feasibility of the C–N coupling. Whereas **3a** reacted in 3 h at room temperature to give compound **5a** in 88% yield, derivative **3b** required heating at 60 °C for 24 h to produce a 30% yield of 2-methyl-4,5-dihydro-2*H*-benzo[*c*] azepine-1,3-dione (**5b**), which was identified by its NMR data.⁴⁰ The reaction mixture also contained several unidentified species that reverted to complex **3b** upon evaporation of the solvent, which suggests that they are CO insertion or coordination products. This result confirmed that the methyl substituent of the amide function is a major obstacle for the C–N coupling step, consistent with our previous findings that the C–N couplings of *ortho*-palladated phenyl-acetamides are generally much slower for NHMe derivatives than for their NH₂ homologues.³⁰

The reactions of palladacycles **2** and **3** with CO are related to those of cyclopalladated arylalkylamines, which may afford esters⁴¹ or lactams.^{27–29,34,42–44} The lack of reactivity of the NMe₂ derivative **2c** contrasts with the ability of classical cyclopalladated *N*,*N*-dialkylbenzylamines to give C–N reductive coupling products after the insertion of CO into the Pd–C bond by losing one of the alkyl groups.^{34,42}

Reactions with XyNC. Isocyanides insert into the Pd–C bond of organopalladium complexes to give iminoacyl derivatives.^{34,45,46} These reactions have been the subject of considerable interest because of their involvement in many stoichiometric^{14,27,29,43,47} and catalytic⁴⁸ palladium-mediated syntheses. The reactions of **1a**–**c** with 3 equiv of XyNC (Xy = 2,6-dimethylphenyl) at room temperature gave the iminoacyl complexes *trans*-[Pd{C(=NXy)C₆H₄(CH₂)₂C(O)NRR'-2}I-(CNXy)₂] [NRR' = NH₂ (**6a**), NHMe (**6b**), NMe₂ (**6c**)], which result from the displacement of the tmeda ligand by two of the isocyanide molecules and the insertion of a third isocyanide into the Pd–C bond. Complexes **6a–c** were also obtained when using only 1 equiv of isocyanide at room

temperature, leaving two-thirds of the starting complex unreacted. The behavior of **1a**–**c** toward XyNC is quite usual for arylpalladium derivatives^{20,37,46,49} but differs from that of the analogous ortho-palladated phenylacetamides [Pd-{C₆H₄CH₂C(O)NRR'-2}I(tmeda)], which react with 1 equiv of the isocyanide to give iminoisoquinoline or iminoisocoumarin derivatives resulting from an insertion/C–N or C–O reductive coupling sequence.³⁰ This is a clear indication that the C–N or C–O couplings are much more difficult for the phenylpropanamide derivatives, in agreement with the behavior of acyl complex **4**.

We then attempted the 1:1 reaction of 1a with XyNC in CHCl₃ at reflux temperature, which gave a precipitate of Pd metal, (tmedaH)I, and an approximately 1:0.85 mixture of 1-[(2,6-dimethylphenyl)imino]-1,2,4,5-tetrahydro-3*H*-2-benzazepin-3-one (7a) and 2-(2-cyanoethyl)-N-(2,6-dimethylphenyl)benzamide (8a). A similar mixture, but with a higher proportion of 8a (0.45:1), was obtained when complex 6a was stirred at reflux temperature in CHCl₃. Thus, two competing transformations of iminoacyl intermediates take place: (i) an intramolecular C-N reductive coupling leading to compound 7a, and (ii) the hydrolysis of the iminoacyl ligand, which is accompanied by the dehydration of the unsubstituted carbamoyl group to give 8a. We have previously shown that a similar hydrolysis/dehydration sequence takes place when the eight-membered palladacycle $[Pd{\kappa^2C,O-C(Ph)=C(Ph)} C_{6}H_{4}CH_{2}C(O)NH_{2}-2$ (tmeda)]TfO reacts with 4 equiv of XyNC.²² The reactions of complexes 1b or 1c with XyNC in 1:1 molar ratio in CHCl₃ at reflux temperature gave mixtures of products that could not be identified.

Reactions with Alkynes. The reactions of in situ generated solutions of complexes 2 in CH₂Cl₂ with various alkynes at room temperature afforded high yields of the nine-membered NRR'-2{(tmeda)]TfO [NRR' = NH_2 , X = Ph (9a), $C_6H_4^{"}Bu-4$ (10a), C_6H_4Br-4 (11a), CO_2Me (12a); NRR' =NHMe, X = Ph (9b); NRR' = NMe₂, X = Ph (9c)], resulting from the insertion of one molecule of the alkyne into the Pd–C bond (Scheme 2). These reactions required the use of strictly 1 equiv of the alkyne and were complete in less than 3 h, except for the case of 11a, which required 20 h. The use of an excess of alkyne led to complex mixtures, probably as a result of polyinsertion reactions. These monoinsertions are thus, in general, considerably faster than those from the six-membered palladacycles [Pd{ $\kappa^2 C$, O-C₆H₄CH₂C(O)NRR'-2}(tmeda)]-TfO, previously reported by us,²² which require an excess of the alkyne and longer reaction times. Presumably, the larger size of palladacycles 2 facilitates the ring-opening and the alkyne coordination step. The IR spectra of complexes 9-12show the ν (C=O) band in the range 1651–1592 cm⁻¹, indicating that the amide function remains coordinated to the metal through the oxygen atom, which was confirmed by the crystal structure of 9a (see below).

The reaction of **2a** with 3-hexyne gave the complex $[Pd{\eta^3}-C_6H_4(C_4Et_4)(CH_2)_2C(O)NH_2\}$ (tmeda)]TfO (**13**), which contains a spirocyclic ligand coordinated to Pd through a η^3 -allylic bond (Scheme 2). This type of ligand has been previously reported to arise from the insertion of two molecules of the alkyne and a subsequent cyclization of the resulting butadienyl fragment.^{18,19,50} Complex **13** was obtained in high yield by using an excess of 3-hexyne, but it is also formed when only 1 equiv of this alkyne is employed and the reaction is carried out at low temperatures, and therefore a monoinsertion product

Scheme 2



analogous to complexes 9-12 could not be isolated. The proclivity of 3-hexyne to give polyinsertion products is typical of electron-rich alkynes, for which it is often impossible to isolate the monoinsertion product.⁵¹

Reactions of Alkyne-Monoinsertion Products with CO. Synthesis of 1,2-dihydro-4H-benzo[e]azonine-3,5diones. Treatment of palladacycles 9a, 10a and 11a with CO (1.4 bar) at 50 °C in CHCl₃ for 15 h gave colloidal Pd, (tmedaH)TfO, and the corresponding 6,7-disubstituted 1,2dihydro-4H-benzo[e]azonine-3,5-diones (14, 15, 16), which were isolated in moderate to good yields (Scheme 2). These heterocycles are the expected products from a CO insertion/ C-N reductive coupling sequence. Only a few nine-membered cyclic imides have been previously reported, which were synthesized via ring expansion reactions⁵² or oxidation of ninemembered lactams.⁵³ Under the same reaction conditions, complex 12a, containing inserted dimethylacetylenedicarboxylate (DMAD), was recovered unreacted, probably because the low nucleophilicity of the vinylic carbon bonded to palladium hampers the CO insertion step.

The reactions of NHMe and NMe₂ derivatives (9b and 9c, respectively) gave mixtures of unidentified compounds. As previously noted for the seven-membered precursors, the failure to give C–N or C–O coupling products can be ascribed to the steric hindrance of the methyl substituent in 9b and/or the lower acidity of the NH and α -CH₂ protons in both cases.

Crystal Structures. The crystal structure of complex 1b is shown in Figure 1. As usually observed for ortho-substituted arylpalladium derivatives, the aromatic ring of the aryl ligand is almost perpendicular to the Pd coordination mean plane, which can be attributed to the steric demand of the ortho substituent. The coordination environment and bond distances and angles around the Pd center are similar to those found in analogous derivatives.^{30,33,36,54} Molecules are linked via hydrogen bonds N–H…I to form zigzag chains parallel to the *c* axis.

The amidate group of complex 3a is coordinated to the Pd atom through the nitrogen, forming a seven-membered ring

with a folded conformation (Figure 2). The Pd–N(1) bond distance of 2.0165(11) Å is similar to that found in the sixmembered cyclic amidate $[Pd{\kappa^2C_1N-C_6H_4CH_2C(O)NMe-2}(dbby)]$ [2.012(3), 2.009(3) Å;³⁰ dbbyy = 4,4'-di-*tert*butyl-2,2'-bipyridyl] and is typical of palladium amidate complexes.⁵⁵ The C(9)–O(1) bond length of 1.2566(16) Å is longer than the corresponding distance in the free propanamide group of **1b** [1.223(2) Å], which can be ascribed to a significant delocalization of the negative charge over the N—C=O group. The molecules are linked into loose inversion-symmetric dimers by weak contacts N–H…Pd and C–H_{methyl}…O.

The crystal structure of compound **8a** is shown in Figure 3. The asymmetric unit contains two pairs of independent molecules; each pair participates in an infinite chain parallel to the *a* axis, whereby the molecules are linked through N— $H \cdots O = C$ hydrogen bonds between the amide groups.

The crystal structure of complex 9a (Figure 4) shows that the diphenylacetylene molecule has inserted in a syn fashion, as usual for alkyne monoinsertions, while the amide group remains coordinated to the Pd through the oxygen. The conformation of the resulting C,O-palladacycle can be approximately described as boat-chair. The square-planar coordination environment around the Pd center is slightly distorted, mainly because of the small bite of the tmeda ligand [angle N(2)–Pd–N(3): $85.59(4)^{\circ}$], while the nine-membered ring does not seem to cause any strain, as deduced from the C(1)-Pd-O(1) angle of 90.47(4)°. The Pd-C(1) bond distance of 2.0039(11) Å is typical of vinylpalladium complexes.^{13,16–18,20,56} The Pd–O(1) distance of 2.0498(9) Å is slightly shorter than that found in the eight-membered palladacycle $[Pd{\kappa^2C, O-C(Ph)=C(Ph)C_6H_4CH_2C(O)NH_2-}]$ $^{2}(\text{tmeda})$]TfO [2.0682(11) Å].²² The two H atoms of the NH₂ group are each involved in a hydrogen bond with one oxygen atom of different triflate anions.

The structure of complex 13 (Figure 5) was solved as a CH_2Cl_2 monosolvate. The spirocyclic ligand is coordinated to palladium via η^3 -allylic interaction through the atoms C6, C7, and C8. The coordination environment around the metal is similar to that found in analogous $[Pd(\eta^3-allyl)(tmeda)]^+$ derivatives.⁵⁷ The cations are linked by hydrogen bonds N–H…O across inversion centers; the triflate anion is connected to the amide moiety and to the CH_2Cl_2 molecule through one N–H…O and two short C–H…O hydrogen bonds. The extended structure consists of inversion-symmetric dimers (see Supporting Information).

The crystal structure of compound 14 is shown in Figure 6. The nine-membered ring exhibits a boat-like conformation. The ring strain is revealed by the C(3)-N(4)-C(5) angle of $134.31(8)^{\circ}$, which is appreciably wider than the average value of 125.2° found for acyclic imides in the Cambridge Structural Database. There are no reported structures of cyclic imides of this size available for comparison, and the only three eightmembered examples display similar C–N–C angles.^{22,58} The molecules of 14 form inversion-related dimers through hydrogen bonds $N(4)-H(04)\cdots O(3)$ #1 (see the Supporting Information).

CONCLUSIONS

Ortho-palladated 3-phenylpropanamides are suitable precursors for the synthesis of seven-membered cationic or neutral palladacycles. The reactions of the former with alkynes have allowed the isolation of nine-membered palladacycles, which, to



Figure 1. Above: Thermal ellipsoid plot (50% probability) of complex **1b**. Selected bond distances (Å) and angles (deg): Pd-C(1) 2.015(2), Pd-N(2) 2.2052(16), Pd-N(3) 2.1240(15), Pd-I 2.5827(2); C(1)-Pd-N(3) 92.23(6), N(3)-Pd-N(2) 83.92(6), C(1)-Pd-I 87.83(5), N(2)-Pd-I 96.14(4), C(6)-C(1)-Pd 117.17(14), C(2)-C(1)-Pd 123.40(15). Below: Association of molecules of **1b** via the *c* glide plane. Hydrogen bonds are indicated by dashed lines.

the best of our knowledge, are the first of that size obtained from alkyne monoinsertions. A series of seven- or ninemembered cyclic imides and one iminobenzazepinone have been obtained from CO or XyNC insertion/C–N reductive coupling sequences.

When compared to analogous cyclopalladated phenylacetamides, the reactivity of the palladacycles described in this article shows important differences, which are mainly attributable to their larger ring size. These can be summarized in two main points: (1) The insertions of alkynes into the Pd-C bond of seven-membered cationic palladacycles are, in most cases, considerably faster: the monoinsertion product can be isolated for diarylalkynes and dimethylacetylenedicarboxylate by using strictly 1 equiv of the alkyne, whereas 3-hexyne gave a di-insertion product containing a spirocyclic ligand coordinated through an η^3 -allylic bond. (2) Cyclizations via C–N couplings after the insertion of CO or XyNC into the Pd-C bond proved to be more difficult and were only satisfactory when starting from the palladacyclic derivatives with the unsubstituted amide function; in the cases of NHMe derivatives, the C-N couplings are hampered because of the steric hindrance of the methyl substituent and the lower acidity of the NH proton.

EXPERIMENTAL SECTION

General Considerations, Materials, and Instrumentation. Unless otherwise noted, all preparations were carried out at room temperature under atmospheric conditions. Synthesis grade solvents were obtained from commercial sources. CH₂Cl₂ was degassed and dried using a Pure Solv MD-5 solvent purification system from Innovative Technology, Inc. $[Pd_2(dba)_3]$ -dba was prepared following the reported procedure.⁵⁹ The compounds 3-(2-iodophenyl)propanamide, 3-(2-iodophenyl)-N-methylpropanamide, and 3-(2iodophenyl)-N,N-dimethylpropanamide were prepared via coppercatalyzed halogen exchange⁶⁰ from the corresponding bromo compounds, which in turn were obtained from commercially available 3-(2-bromophenyl)propanoic acid (see the Supporting Information). All other reagents were obtained from commercial sources and used without further purification. NMR spectra were recorded on Bruker Avance 200, 300, or 400 spectrometers at 298 K. Chemical shifts are referred to internal TMS. The assignments of the ¹H and ${}^{13}C{}^{1}H$ NMR spectra were made with the help of HMQC and HMBC experiments. Inserted and coordinated XyNC are denoted by XyNCⁱ and XyNC^c, respectively, and the 1,2-C₆H₄ arylene group is denoted by Ar. Melting points were determined on a Reichert apparatus and are uncorrected. Elemental analyses were carried out with Carlo Erba 1106 and LECO CHNS-932 microanalyzers. Infrared spectra were recorded in the range 4000-200 cm⁻¹ on a Perkin-Elmer Spectrum 100 spectrophotometer using Nujol mulls between polyethylene sheets or CH₂Cl₂ solutions. High-resolution ESI mass spectra were recorded on an Agilent 6220 Accurate-Mass TOF LC/MS.



Figure 2. Above: Thermal ellipsoid plot (50% probability) of complex **3a**. Selected bond distances (Å) and angles (deg): Pd–C(1) 1.9875(12), Pd–N(1) 2.0165(11), Pd–N(2) 2.1058(11), Pd–N(3) 2.1882(11), C(9)–O(1) 1.2566(16), C(9)–N(1) 1.3337(17); C(1)–Pd–N(1) 88.66(5), C(1)–Pd–N(2) 92.80(5), N(1)–Pd–N(3) 94.28(4), N(2)–Pd–N(3) 84.28(4), C(2)–C(7)–C(8) 111.28(11), C(9)–C(8)–C(7) 120.52(11), O(1)–C(9)–N(1) 123.43(12), O(1)–C(9)–C(8) 116.18(12), N(1)–C(9)–C(8) 120.32(12), C(9)–N(1)–Pd 134.03(9). Below: A loose dimer of **3a**, with weak hydrogen bonds N–H…Pd (2.94 Å) and C–H_{methyl}…O (2.49 Å) indicated as dashed lines.

X-ray Structure Determinations. Crystals suitable for X-ray diffraction studies were obtained by liquid-liquid diffusion from CH₂Cl₂/Et₂O (1b), CH₂Cl₂/n-pentane (3a), CDCl₃/n-pentane (8a), CDCl₃/Et₂O (9a), CH₂Cl₂/n-pentane (13·CH₂Cl₂), Et₂O/n-hexane (14). Numerical details are given in the Supporting Information (Table S1). The data for 1b, 3a, 8a, 9a, and 13·CH₂Cl₂ were collected on an Oxford Diffraction Xcalibur diffractometer using monochromated Mo K α radiation in ω -scan mode. The data for 14 were collected on an Oxford Diffraction Nova diffractometer using mirrorfocused Cu K α radiation in ω -scan mode. Absorption corrections were based on multiscans. The structures were solved by direct methods and refined anisotropically on F^2 using the program SHELXL-97 (G. M. Sheldrick, University of Göttingen).⁶¹ Treatment of hydrogen atoms was as follows: NH hydrogens were refined freely, methyl hydrogens incorporated into idealized rigid groups allowed to rotate but not tip, other H using a riding model starting from calculated positions.

Exceptions and Special Features. For **1b**, the two largest difference peaks lay near C2. These could not be interpreted and may be caused by unidentified twinning or disorder phenomena. For **3a**, the TMEDA group is slightly disordered, with the minor position being occupied to the extent of 7%. For **8a**, no absorption correction was applied. This

compound crystallizes by chance in a Sohncke space group; in the absence of significant anomalous dispersion, Friedel opposite reflections were merged, and the absolute structure is thus indeterminate. For 13·CH₂Cl₂, H atoms at coordinated C atoms were refined freely, but all freely refined hydrogens were subjected to NH or CH distance restraints.

Synthesis of $[Pd{C_6H_4(CH_2)_2C(O)NRR'-2}](tmeda)]$ $[NRR' = NH_2$ (1a), NHMe (1b), NMe₂ (1c)]. To a suspension of Pd(dba)₂ (903 mg, 1.57 mmol) in CH₂Cl₂ (20 mL) were added tmeda (0.3 mL, 2.00 mmol) and 3-(2-iodophenyl)propanamide, 3-(2-iodophenyl)-*N*-methylpropanamide, or 3-(2-iodophenyl)-*N*,*N*-dimethylpropanamide (1.57 mmol), and the mixture was stirred for 1 h under an N₂ atmosphere. The resulting black suspension was filtered through anhydrous MgSO₄, and the clear orange filtrate was concentrated (1 mL). The addition of Et₂O (20 mL) led to the precipitation of a pale orange solid, which was filtered off, washed with Et₂O (5 × 3 mL), recrystallized from CH₂Cl₂/Et₂O, and vacuum-dried to give the corresponding complex 1.

1a. Yield: 68%. Anal. Calcd for C₁₅H₂₆IN₃OPd: C, 36.20; H, 5.27; N, 8.44. Found: C, 35.82; H, 5.22; N, 8.20. Mp: 147–152 °C (dec). IR (Nujol, cm⁻¹): ν (NH), 3370, 3156; ν (CO), 1652. ¹H NMR (400.9 MHz, CDCl₃): δ 7.27–7.23 (m, 1 H, Ar), 6.89–6.86 (m, 1 H, Ar), 6.85–6.77 (m, 2 H, Ar), 6.03 (br, 1 H, NH), 5.30 (br, 1 H, NH), 3.84, 3.23 (AB part of ABXY system, ²J_{AB} = 12.8 Hz, ³J_{AX} = ³J_{BY} = 10.4 Hz, ³J_{AY} = 4.4 Hz, ³J_{BX} = 7.2 Hz, 2 H, CH₂, propanamide), 2.95–2.83 (m, 2 H, CH₂, tmeda + propanamide), 2.71 (s, 3 H, Me), 2.66 (s, 3 H, Me), 2.69–2.49 (m, 4 H, CH₂, tmeda + propanamide), 2.43 (s, 3 H, Me), 2.15 (s, 3 H, Me). ¹³C{¹H} APT NMR (100.8 MHz, CDCl₃): δ 176.2 (CO), 143.72, 143.66 (C, Ar), 135.9, 127.1, 124.6, 123.2 (CH, Ar), 62.1, 58.2 (CH₂, tmeda), 50.4, 50.2, 49.1, 48.7 (Me), 36.7, 35.9 (CH₂, propanamide).

1b. Yield: 67%. Anal. Calcd for C₁₆H₂₈IN₃OPd: C, 37.55; H, 5.51; N, 8.21. Found: C, 37.31; H, 5.50; N, 7.83. Mp: 142–145 °C (dec). IR (Nujol, cm⁻¹): ν (NH), 3384; ν (CO), 1656. ¹H NMR (400.9 MHz, CDCl₃): δ 7.24 (m, 1 H, Ar), 6.87–6.76 (m, 3 H, Ar), 6.01 (br c, ³J_{HH} = 4.8 Hz, 1 H, NH), 3.78, 3.24 (AB part of ABXY system, ²J_{AB} = 12.8 Hz, ³J_{AX} = ³J_{BY} = 10.0 Hz, ³J_{AY} = 4.4 Hz, ³J_{BX} = 7.6 Hz, 2 H, CH₂, propanamide), 2.89–2.76 (m, 2 H, CH₂, tmeda + propanamide), 2.73 (d, ³J_{HH} = 4.8 Hz, 3 H, NHM*e*), 2.71 (s, 3 H, Me, tmeda), 2.66 (s, 3 H, Me, tmeda), 2.69–2.48 (m, 4 H, CH₂, tmeda + propanamide), 2.43 (s, 3 H, Me, tmeda), 2.15 (s, 3 H, Me, tmeda). ¹³C{¹H} APT NMR (100.8 MHz, CDCl₃): δ 174.3 (CO), 143.8, 143.6 (C, Ar), 135.9, 127.1, 124.5, 123.2 (CH, Ar), 62.1, 58.2 (CH₂, tmeda), 50.3, 50.2, 49.2, 48.7 (Me, tmeda), 37.2, 36.0 (CH₂, propanamide), 26.0 (NHMe).

1c. Yield: 55%. Anal. Calcd for C₁₇H₃₀IN₃OPd: C, 38.84; H, 5.75; N, 7.99. Found: C, 38.48; H, 5.81; N, 7.88. Mp: 170 °C (dec). IR (Nujol, cm⁻¹): ν (CO), 1639. ¹H NMR (400.9 MHz, CDCl₃): δ 7.26–7.22 (m, 1 H, Ar), 6.88–6.85 (m, 1 H, Ar), 6.82–6.77 (m, 2 H, Ar), 3.83–3.74 (m, 1 H, CH₂, propanamide), 3.29–3.16 (m, 2 H, CH₂, tmeda + propanamide), 3.00 (s, 3 H, Me, propanamide), 2.96 (s, 3 H, Me, propanamide), 2.69 (s, 3 H, Me, tmeda), 2.65 (s, 3 H, Me, tmeda), 2.69–2.42 (m, 4 H, CH₂, tmeda + propanamide), 2.40 (s, 3 H, Me, tmeda), 2.19 (s, 3 H, Me, tmeda). ¹³C{¹H} APT NMR (100.8 MHz, CDCl₃): δ 173.6 (CO), 144.6, 143.8 (C, Ar), 136.1, 127.1, 124.2, 123.0 (CH, Ar), 62.0, 58.2 (CH₂, tmeda), 50.3, 50.2, 49.2, 48.8 (Me, tmeda), 37.6, 35.3 (Me, propanamide), 34.9, 34.3 (CH₂, propanamide).

Synthesis of $[Pd{\kappa^2C,O-C_6H_4(CH_2)_2C(O)NRR'-2}(tmeda)]TfO$ [NRR' = NH₂ (2a), NHMe (2b), NMe₂ (2c)]. To a solution of the appropriate complex 1 (0.25 mmol) in acetone (20 mL) was added AgTfO (63 mg, 0.25 mmol), and the mixture was stirred for 30 min. The solvent was removed under reduced pressure, the residue was extracted with CH₂Cl₂ (6 × 5 mL), and the combined extracts were filtered through anhydrous MgSO₄. Partial evaporation of the filtrate (1 mL) and addition of Et₂O (20 mL) led to the precipitate was thoroughly dried under vacuum to give the corresponding complex 2 as a pale yellow solid. Reprecipitations from acetone/Et₂O or CH₂Cl₂/

Article



Figure 3. Above: Thermal ellipsoid plot (50% probability), hydrogen bonds and crystal packing of compound 8a. Selected bond distances (Å) and angles (deg) of one of the four independent molecules: C(1)-C(7) 1.497(3), C(7)-O(1) 1.238(2), C(7)-N(1) 1.345(3), C(11)-N(1) 1.435(3), C(10)-N(2) 1.143(3); O(1)-C(7)-N(1) 122.0(2), O(1)-C(7)-C(1) 121.2(2), N(1)-C(7)-C(1) 116.77(18), C(7)-N(1)-C(11) 121.02(17), N(2)-C(10)-C(9) 179.5(3). Below: Packing diagram of 8a, showing chains of molecules linked by hydrogen bonds (dashed lines). The upper chain consists of molecules 3, 4, 3, 4, ..., and the lower chain of 2, 1, 2, 1, ..., in each case starting from the left.

 ${\rm Et_2O}$ did not improve the purity of the products, and acceptable elemental analyses were obtained only for 2b.

2a. Yield: 84%. IR (CH₂Cl₂, cm⁻¹): ν (CO), 1646. HRMS (ESI+, m/z): exact mass calcd for C₁₅H₂₆N₃OPd [M]⁺ requires 370.1111, found 370.1103, error = 2.16 ppm. HRMS (ESI-, m/z): exact mass calcd for CF₃O₃S [M]⁻ requires 148.9526, found 148.9532, error = 4.03 ppm. ¹H NMR (300.1 MHz, CDCl₃): δ 7.84 (br, 1 H, NH), 7.06–7.02 (m, 1 H, Ar), 6.96–6.92 (m, 2 H, Ar), 6.86–6.81 (m, 1 H, Ar), 6.42 (br, 1 H, NH), 4.41 (m, 1 H, CH₂ propanamide), 3.05–2.95 (m, 2 H, CH₂, tmeda + propanamide), 2.81 (s, 3 H, Me), 2.79–2.62 (m, 5 H, CH₂, tmeda + propanamide), 2.58 (s, 3 H, Me), 2.50 (s, 3 H, Me), 2.46 (s, 3 H, Me). ¹³C{¹H} APT NMR (75.5 MHz, CDCl₃): δ 181.0 (CO), 145.5, 143.0 (C, Ar), 132.0, 126.6, 126.0, 125.1 (CH, Ar), 64.3, 57.2 (CH₂, tmeda), 53.7, 50.3, 47.9, 46.7 (Me), 34.1, 30.7 (CH₂, propanamide).

2b. Yield: 91%. Anal. Calcd for $C_{17}H_{28}F_3N_3O_4PdS$: C, 38.24; H, 5.29; N, 7.87; S, 6.01. Found: C, 38.17; H, 5.26; N, 7.86; S, 6.31. Mp: 60–65 °C (dec). IR (CH_2Cl_2 , cm^{-1}): $\nu(CO)$, 1608. HRMS (ESI+, m/z): exact mass calcd for $C_{16}H_{28}N_3OPd$ [M]⁺ requires 384.1267, found 384.1274, error = 1.82 ppm. HRMS (ESI-, m/z): exact mass calcd for CF_3O_3S [M]⁻ requires 148.9526, found 148.9529, error = 2.26 ppm. ¹H NMR (300.1 MHz, CDCl₃): δ 8.17 (br c, ³ J_{HH} = 4.8 Hz, NH), 7.06–7.02 (m, 1 H, Ar), 6.96–6.89 (m, 2 H, Ar), 6.83–6.79 (m, 1 H, Ar), 4.44 (m, 1 H, CH₂ propanamide), 3.15–2.88 (m, 3 H, CH₂, tmeda + propanamide), 2.86–2.58 (m, 4 H, CH₂, tmeda + propanamide), 2.82 (s, 3 H, Me, tmeda), 2.65 (s, 3 H, Me, tmeda), 2.63 (d, ³ J_{HH} = 4.8 Hz, NHMe), 2.53 (s, 3 H, Me, tmeda), 2.44 (s, 3 H, Me, tmeda). ¹³C{¹H} APT NMR (75.5 MHz, CDCl₃): δ 178.0 (CO), 145.4, 142.9 (C, Ar), 131.9, 126.6, 125.8, 125.0 (CH, Ar), 64.3, 57.2

Article



Figure 4. Thermal ellipsoid plot (50% probability) and hydrogen bonds (dashed lines) in an inversion-symmetric dimer of complex 9a. Selected bond distances (Å) and angles (deg): Pd-C(1) 2.0039(11), Pd-O(1) 2.0498(9), Pd-N(2) 2.0889(10), Pd-N(3) 2.1524(11), O(1)-C(11) 1.2547(15), N(1)-C(11) 1.3199(17), C(1)-C(2) 1.3534(16), C(2)-C(3) 1.5015(16); C(1)-Pd-O(1) 90.47(4), C(1)-Pd-N(2) 96.38(4), O(1)-Pd-N(3) 87.44(4), N(2)-Pd-N(3) 85.59(4), C(11)-O(1)-Pd 134.38(8), C(2)-C(1)-Pd 118.42(9), C(1)-C(2)-C(3) 119.94(10), C(4)-C(9)-C(10) 112.69(10), C(11)-C(10)-C(9) 111.75(10), O(1)-C(11)-N(1) 123.21(12), O(1)-C(11)-C(10) 117.48(11), N(1)-C(11)-C(10) 119.31(11).



Figure 5. Thermal ellipsoid plot (50% probability) of complex 13. Selected bond distances (Å) and angles (deg): Pd-C(6) 2.2193(12), Pd-C(7) 2.0828(12), Pd-C(8) 2.1385(12), Pd-N(2) 2.2027(11), Pd-N(3) 2.1708(11), O(1)-C(13) 1.2361(17), N(1)-C(13) 1.3359(19), C(1)-C(2) 1.3484(19), C(1)-C(5) 1.5218(17), C(2)-C(3) 1.480(2), C(3)-C(4) 1.3491(17), C(3)-C(18)1.5030(18), C(4)-C(5) 1.5336(17), C(5)-C(10) 1.5231(17), C(5)-C(6) 1.5255(17), C(6)-C(7) 1.4076(17), C(7)-C(8)1.4186(18), C(8)-C(9) 1.4662(17), C(9)-C(10) 1.3425(17); N(3)-Pd-N(2) 83.19(4), C(7)-Pd-N(2) 134.17(5), C(8)-Pd-N(2) 172.91(5), C(7)-Pd-N(3) 127.03(5), C(8)-Pd-N(3) 99.94(4), C(7)-Pd-C(8) 39.25(5), C(7)-Pd-C(6) 38.03(5), C(8)-Pd-C(6) 65.85(5), N(3)-Pd-C(6) 164.72(4), N(2)-Pd-C(6) 110.31(4), C(7)-C(6)-C(5) 118.87(11), C(6)-C(7)-C(8)113.96(11), C(7)-C(8)-C(9) 119.70(11), O(1)-C(13)-N(1) 122.72(13), O(1)-C(13)-C(12) 119.71(13), N(1)-C(13)-C(12) 117.57(12).

(CH₂, tmeda), 53.9, 50.0, 48.1, 46.5 (Me, tmeda), 34.6, 30.9 (CH₂, propanamide), 26.8 (NHMe).



Figure 6. Thermal ellipsoid plot (50% probability) and crystal packing of compound 14. Selected bond distances (Å) and angles (deg): C(1)-C(2) 1.5566(14), C(2)-C(3) 1.5060(13), C(3)-O(3) 1.2232(12), C(3)-N(4) 1.3865(13), N(4)-C(5) 1.3911(13), C(5)-O(5) 1.2165(12), C(5)-C(6) 1.5150(13), C(6)-C(7) 1.3466(14); C(11A)-C(1)-C(2) 115.88(8), C(3)-C(2)-C(1) 110.73(8), O(3)-C(3)-N(4) 117.94(9), O(3)-C(3)-C(2) 120.96(9), N(4)-C(3)-C(2) 121.09(8), C(3)-N(4)-C(5) 134.31(8), O(5)-C(5)-N(4) 117.94(9), O(5)-C(5)-C(6) 119.33(9), N(4)-C(5)-C(6) 122.69(8), C(7)-C(6)-C(5) 118.94(9), C(6)-C(7)-C(7A) 118.26(8).

2c. Yield: 58%. IR (CH₂Cl₂, cm⁻¹): ν (CO), 1591. HRMS (ESI+, m/z): exact mass calcd for C₁₇H₃₀N₃OPd [M]⁺ requires 398.1424, found 398.1437, error = 3.27 ppm. HRMS (ESI-, m/z): exact mass calcd for CF₃O₃S [M]⁻ requires 148.9526, found 148.9530, error = 3.20 ppm. ¹H NMR (400.9 MHz, CDCl₃): δ 7.08–7.04 (m, 1 H, Ar), 6.98–6.91 (m, 2 H, Ar), 6.85–6.82 (m, 1 H, Ar), 4.66 (td, ³J_{HH} = 3.2 Hz, ²J_{HH} = 13.6 Hz, 1 H, CH₂ propanamide), 3.19–3.09 (m, 2 H, CH₂, tmeda + propanamide), 3.00 (s, 3 H, Me, propanamide), 2.97–2.94 (m, 1 H, CH₂), 2.89 (s, 3 H, Me, propanamide), 2.82 (s, 3 H, Me, tmeda), 2.82 (s, 3 H, CH₂), 2.64 (s, 3 H, Me, tmeda), 2.62 (s, 3 H, Me, tmeda), 2.62 (s, 3 H, CH₂), 2.64 (s, 3 H, Me, tmeda), 2.62 (s, 3 H, Me, tmeda), 2.62 (s, 3 H, CH₂), 2.64 (s, 3 H, Me, tmeda), 2.62 (s, 3 H, ME, tmeda), 2.62 (s, 3 H, CH₂), 2.64 (s, 3 H, Me, tmeda), 2.62 (s, 3 H, CH₂), 2.64 (s, 2 H, Me, tmeda), 2.62 (s, 3 H, ME, tmeda), 2.62 (s, 3 H, ME, tmeda), 2.62 (s, 3 H, CH₂), 2.64 (s, 2 H, ME, tmeda), 2.62 (s, 3 H, CH₂), 2.64 (s, 2 H, ME, tmeda), 2.62 (s, 3 H, CH₂), 2.64 (s, 2 H, ME, tmeda), 2.62 (s, 3 H, CH₂), 2.64 (s, 2 H, ME, tmeda), 2.62 (s, 3 H, CH₂), 2.64 (s, 2 H, ME, tmeda), 2.62 (s, 3 H, CH₂), 2.64 (s, 2 H, ME, tmeda), 2.62 (s, 3 H, CH₂), 2.64 (s, 2 H, ME, tmeda), 2.62 (s, 3 H, CH₂), 2.64 (s, 2 H, ME, tmeda), 2.62 (s, 3 H, CH₂), 2.64 (s, 2 H, ME, tmeda), 2.62 (s, 3 H, CH₂), 2.64 (s, 2 H, ME, tmeda), 2.62 (s, 3 H, CH₂), 2.64 (s, 2 H, ME, tmeda), 2.62 (s, 3 H, CH₂), 2.64 (s, 2 H, ME, tmeda), 2.62 (s, 3 H, CH₂), 2.64 (s, 2 H, ME, tmeda), 2.62 (s, 3 H, CH₂), 2.64 (s, 2 H, ME, tmeda), 2.62 (s, 3 H, CH₂), 2.64 (s, 2 H, ME, tmeda), 2.62 (s, 3 H, CH₂), 2.64 (s, 2 H, ME, tmeda), 2.62 (s, 3 H, CH₂), 2.64 (s, 2 H, ME, tmeda), 2.62 (s, 3 H, ME

H, Me, tmeda), 2.57–2.47 (1 H, CH₂), 2.48 (s, 3 H, Me, tmeda). ${}^{13}C{}^{1}H$ APT NMR (100.8 MHz, CDCl₃): δ 176.0 (CO), 145.6, 143.4 (C, Ar), 132.0, 126.2, 125.9, 124.9 (CH, Ar), 64.4, 57.2 (CH₂, tmeda), 54.0, 50.1, 48.1, 46.7 (Me, tmeda), 38.0, 37.0 (Me, propanamide), 34.1, 31.1 (CH₂, propanamide).

Synthesis of $[Pd\{\kappa^2C,N-C_6H_4(CH_2)_2C(O)NR-2\}(tmeda)]$ [R = H (3a), Me (3b)]. To a solution of 1a or 1b (0.46 mmol) in CH₂Cl₂ (25 mL) was added KO'Bu (414 mg, 3.69 mmol), and the resulting suspension was stirred for 4 h and then filtered through Celite. Partial evaporation of the pale yellow filtrate (3 mL) and slow addition of *n*-pentane (20 mL) led to the precipitation of a colorless solid, which was filtered off, recrystallized from CH₂Cl₂/*n*-pentane, and vacuum-dried to give the corresponding complex 3.

3a. Yield: 83%. Anal. Calcd for $C_{15}H_{25}N_3OPd: C, 48.72; H, 6.81; N, 11.36. Found: C, 48.54; H, 7.21; N, 11.21. Mp: 140–143 °C (dec). IR (Nujol, cm⁻¹): <math>\nu$ (CO), 1551. ¹H NMR (400.9 MHz, CDCl₃): δ 7.19–7.14 (m, 1 H, Ar), 6.90–6.84 (m, 3 H, Ar), 4.16 (m, 1 H, CH₂, propanamide), 4.09 (br, 1 H, NH), 2.92 (td, ³J_{HH} = 4.0 Hz, ²J_{HH} = 12.8 Hz, 1 H, CH₂, propanamide), 2.85–2.79 (m, 1 H, CH₂, tmeda), 2.68 (s, 3 H, Me, tmeda), 2.72–2.67 (m, 1 H, CH₂, propanamide), 2.55 (s, 3 H, Me, tmeda), 2.66–2.47 (m, 3 H, CH₂, tmeda), 2.44 (s, 3 H, Me, tmeda), 2.31–2.27 (m, 1 H, CH₂, propanamide), 2.27 (s, 3 H, Me, tmeda). ¹³C{¹H} APT NMR (50.3 MHz, CDCl₃): δ 178.4 (CO), 151.4, 145.8 (C, Ar), 132.6, 125.6, 124.5, 123.4 (CH, Ar), 62.4, 58.0 (CH₂, tmeda), 51.9, 48.9, 47.9, 47.2 (Me, tmeda), 37.8, 36.8 (CH₂, propanamide).

3b. This complex was obtained as an hydrate. Yield: 79%. Anal. Calcd for $C_{16}H_{29,4}N_3O_{2,2}Pd: C, 47.40; H, 7.31; N, 10.36. Found: C, 47.33; H, 7.55; N, 10.33. Mp: 108–109 °C. IR (Nujol, cm⁻¹): <math>\nu$ (CO), 1558. ¹H NMR (400.9 MHz, CDCl₃): δ 7.27–7.22 (m, 1 H, Ar), 6.85–6.80 (m, 3 H, Ar), 3.86–3.70 (m, 2 H, CH₂, propanamide), 3.12–3.05 (m, 1 H, CH₂, propanamide), 2.79–2.72 (m, 1 H, CH₂, tmeda), 2.72 (s, 3 H, Me, propanamide), 2.68–2.60 (m, 13 H, Me, CH₂, tmeda + CH₂, propanamide), 2.28 (s, 3 H, Me, tmeda), 1.96 (s, 2 H, H₂O). ¹³C{¹H} APT NMR (100.8 MHz, CDCl₃): δ 176.1 (CO), 149.1, 144.0 (C2, Ar), 132.7, 127.5, 123.9, 122.9 (CH, Ar), 62.1, 58.3 (CH₂, tmeda), 36.4 (Me, propanamide), 33.8 (CH₂, propanamide).

Synthesis of $[Pd{C(0)C_6H_4(CH_2)_2C(0)NH_2-2}](tmeda)]$ (4). CO was bubbled through a stirred solution of 1a (103 mg, 0.21 mmol) in CH₂Cl₂ (10 mL) for 30 min, and the resulting solution was filtered through Celite. Partial evaporation of the filtrate (5 mL) and addition of n-pentane (20 mL) led to the precipitation of a yellow solid, which was collected by filtration, washed with CH_2Cl_2/n -pentane (5 × 5 mL), and vacuum-dried to give 4.0.5CH2Cl2. Yield: 101 mg, 86%. Anal. Calcd for C_{16.5}H₂₇ClIN₃O₂Pd: C, 34.88; H, 4.79; N, 7.40. Found: C, 34.58; H, 5.06; N, 7.24. Mp: 91-94 °C. IR (Nujol, cm⁻¹): ν (NH), 3385, 3144; ν (CO), 1677, 1640. ¹H NMR (400.9 MHz, CDCl₃): δ 9.09 (dd, ⁴J_{HH} = 1.2 Hz, ³J_{HH} = 7.6 Hz, 1 H, Ar), 7.45 (td, ${}^{4}J_{HH} = 1.2$ Hz, ${}^{3}J_{HH} = 7.6$ Hz, 1 H, Ar), 7.31 (td, ${}^{4}J_{HH} = 1.2$ Hz, ${}^{3}J_{HH} = 1.2$ Hz, ${}^{3}J_{H} = 1.2$ 7.6 Hz, 1 H, Ar), 7.11 (dd, ${}^{4}J_{HH}$ = 1.2 Hz, ${}^{3}J_{HH}$ = 7.6 Hz, 1 H, Ar), 6.07 (s, 1 H, NH), 5.30 (s, 1 H, CH₂Cl₂), 5.13 (s, 1 H, NH), 3.17 (m, 2 H, CH₂, propanamide), 2.76 (m, 2 H, CH₂, tmeda), 2.59 (s, 6 H, Me, tmeda), 2.55 (m, 2 H, CH₂, tmeda), 2.52 (s, 6 H, Me, tmeda), 2.49 (m, 2 H, CH₂, propanamide). ¹³C{¹H} APT NMR (75.5 MHz, CDCl₃): δ 175.3 (CONH₂), 139.6 (CH, Ar), 138.4, 136.8 (C, Ar), 130.9, 130.6, 126.2 (CH, Ar), 61.8, 57.6 (CH₂, tmeda), 50.4, 48.9 (Me, tmeda), 37.4, 31.2 (CH₂, propanamide); PdC not observed.

Synthesis of 4,5-Dihydro-2*H*-benzo[*c*]azepine-1,3-dione (5a). To a solution of 1a (134 mg, 0.27 mmol) in acetone (15 mL) was added AgTfO (70 mg, 0.27 mmol), and the resulting suspension was stirred for 15 min. The solvent was removed under vacuum, the residue was extracted with CH₂Cl₂ (6×5 mL), and the combined extracts were filtered through Celite. The filtrate was stirred under a CO atmosphere (1.4 bar) for 6 h, whereupon a black precipitate of Pd gradually formed. The solvent was removed under vacuum, the residue was extracted with a 1:10 CH₂Cl₂/*n*-hexane mixture (6×5 mL), and the combined extracts were filtered through Celite. Evaporation of the solvents under reduced pressure gave 5a as a colorless solid. Yield: 20 mg, 42%. Mp: 115–118 °C. IR (Nujol, cm⁻¹): ν (CO), 1668, 1662.

HRMS (ESI+, *m*/*z*): exact mass calcd for $C_{10}H_{10}NO_2$ [M + H]⁺ requires 176.0706, found 176.0709, error = 1.71 ppm. ¹H NMR (400.9 MHz, CDCl₃): δ 8.36 (br, 1 H, NH), 8.12 (dd, ⁴*J*_{HH} = 1.6 Hz, ³*J*_{HH} = 7.6 Hz, 1 H, H9), 7.52 (td, ⁴*J*_{HH} = 1.6 Hz, ³*J*_{HH} = 7.6 Hz, 1 H, H9), 7.52 (td, ⁴*J*_{HH} = 1.6 Hz, ³*J*_{HH} = 7.6 Hz, 1 H, H7), 7.42 (td, ⁴*J*_{HH} = 1.2 Hz, ³*J*_{HH} = 7.6 Hz, 1 H, H8), 7.23 (m, 1 H, H6), 3.13–3.10 (m, 2 H, H5), 2.91–2.89 (m, 2 H, H4). ¹³C{¹H} APT NMR (100.8 MHz, CDCl₃): δ 173.3 (C3), 166.2 (C1), 140.5 (C5a), 133.6 (C7), 133.1 (C9), 129.9 (C9a), 128.8 (C6), 127.6 (C8), 36.8 (C4), 29.1 (C5).

Synthesis of trans-[Pd{C(=NXy)C₆H₄(CH₂)₂C(0)NRR'-2}I-(CNXy)₂] [NRR' = NH₂ (6a), NHMe (6b), NMe₂ (6c)]. A mixture of the appropriate complex 1 (0.16 mmol) and XyNC (66 mg, 0.50 mmol) in CH₂Cl₂ (20 mL) was stirred for 15 min and filtered through Celite. Partial evaporation of the yellow filtrate (2 mL) and addition of *n*-pentane (30 mL) led to the precipitation of a yellow solid, which was filtered off, recrystallized from CH₂Cl₂/*n*-pentane and vacuum-dried to give the corresponding complex 6.

6a. Yield: 77%. Anal. Calcd for C₃₆H₃₇IN₄OPd: C, 55.79; H, 4.81; N, 7.23. Found: C, 55.63; H, 4.61; N, 7.45. Mp: 138–140 °C (dec). IR (Nujol, cm⁻¹): ν(NH), 3440; ν(C≡N), 2180; ν(CO), 1677; ν(C=N), 1584. ¹H NMR (300.1 MHz, CDCl₃): δ 7.86 (m, 1 H, Ar), 7.33–7.20 (m, 5 H, Ar + p-H, XyNC^c), 7.07 (d, ³J_{HH} = 7.8 Hz, 4 H, m-H, XyNC^c), 6.90 (s, 3 H, XyNCⁱ), 6.24 (br, 1 H, NH), 5.20 (br, 1 H, NH), 3.43–3.71 (m, 2 H, CH₂, propanamide), 2.99–2.94 (m, 2 H, CH₂, propanamide), 2.22 (s, 6 H, Me, XyNCⁱ), 2.20 (s, 12 H, Me, XyNC^c). ¹³C{¹H} APT NMR (75.5 MHz, CDCl₃): δ 178.8 (C=N), 174.6 (CO), 149.9 (*i*-C, XyNCⁱ), 145.1 (C, Ar), 143.0 (br, *i*-C, XyNC^c), 136.7 (C, Ar), 135.6 (o-C, XyNC^c), 130.1 (CH, Ar + XyNC^c), 129.6, 128.8 (CH, Ar), 128.2 (CH, XyNCⁱ), 128.0 (CH, XyNC^c), 127.0 (o-C, XyNCⁱ), 126.6 (CH, Ar), 123.7 (CH, XyNCⁱ), 39.4, 30.4 (CH₂), 19.1 (Me, XyNCⁱ), 18.7 (Me, XyNC^c); C≡N of XyNC^c not observed.

6b. Yield: 74%. Anal. Calcd for $C_{37}H_{39}IN_4OPd$: C, 56.32; H, 4.98; N, 7.10. Found: C, 56.50; H, 5.27; N, 7.10. Mp: 131–133 °C (dec). IR (Nujol, cm⁻¹): ν (NH), 3347; ν (C \equiv N), 2178; ν (CO), 1673; ν (C=N), 1586. ¹H NMR (400.9 MHz, CDCl₃): δ 7.76 (dd, ⁴J_{HH} = 1.2 Hz, ³J_{HH} = 7.2 Hz, 1 H, Ar), 7.34–7.28 (m, 2 H, Ar), 7.27–7.21 (m, 3 H, Ar + p-H, XyNC^c), 7.07 (d, ³J_{HH} = 7.2 Hz, 4 H, m-H, XyNC^c), 6.91 (s, 3 H, XyNCⁱ), 6.33 (br c, ³J_{HH} = 4.8 Hz, 1 H, NH), 3.40–3.35 (m, 2 H, CH₂, propanamide), 2.96–2.92 (m, 2 H, CH₂, propanamide), 2.57 (d, ³J_{HH} = 4.8 Hz, 3 H, NMe), 2.22 (s, 6 H, Me, XyNCⁱ), 2.20 (s, 12 H, Me, XyNC^c). ¹³C{¹H} APT NMR (75.5 MHz, CDCl₃): δ 178.6 (C= N), 172.8 (CO), 149.9 (*i*-C, XyNCⁱ), 145.3 (C, Ar), 143.0 (br, *i*-C, XyNC^c), 137.1 (C, Ar), 135.6 (o-C, XyNC^c), 130.2 (CH, Ar), 130.1 (CH, XyNC^c), 128.8 (CH, Ar), 128.2 (CH, XyNCⁱ), 128.0 (CH, XyNC^c), 127.0 (o-C, XyNCⁱ), 126.6 (CH, Ar), 123.7 (CH, XyNCⁱ), 40.3, 30.9 (CH₂), 25.8 (NMe), 19.1 (Me, XyNCⁱ), 18.7 (Me, XyNC^c); C \equiv N of XyNC^c not observed.

6c. Yield: 79%. Anal. Calcd for C₃₈H₄₁IN₄OPd: C, 56.83; H, 5.15; N, 6.98. Found: C, 56.94; H, 5.34; N, 6.93. Mp: 139−140 °C (dec.). IR (Nujol, cm⁻¹): ν (C≡N), 2174; ν (CO), 1649; ν (C=N), 1590. ¹H NMR (300.1 MHz, CDCl₃): δ 8.08 (d, ³J_{HH} = 7.2 Hz, 1 H, Ar), 7.34−7.19 (m, 5 H, Ar + p-H, XyNC^c), 7.06 (d, ³J_{HH} = 7.5 Hz, 4 H, m-H, XyNC^c), 6.90 (s, 3 H, XyNCⁱ), 3.33−3.28 (m, 2 H, CH₂, propanamide), 2.89−2.84 (m, 2 H, CH₂, propanamide), 2.85 (s, 3 H, NMe), 2.21 (s, 18 H, Me, XyNCⁱ + XyNC^c). ¹³C{¹H} APT NMR (75.5 MHz, CDCl₃): δ 177.8 (C=N), 172.4 (CO), 149.8 (*i*-C, XyNCⁱ), 145.1, 136.8 (C, Ar), 135.6 (*o*-C, XyNC^c), 131.3, 130.6 (CH, Ar), 129.9 (CH, XyNC^c), 128.4 (CH, Ar), 128.0 (CH, XyNCⁱ), 127.9 (CH, XyNC^c), 126.9 (*o*-C, XyNCⁱ), 126.2 (CH, Ar), 123.4 (CH, XyNCⁱ), 37.1 (NMe), 36.5 (CH₂), 35.2 (NMe), 30.3 (CH₂), 19.2 (Me, XyNCⁱ), 18.7 (Me, XyNC^c); *i*-C and C≡N of XyNC^c not observed.

Synthesis of 1-(2,6-Dimethylphenylimino)-1,2,4,5tetrahydrobenzo[c]azepin-3-one (7a) and 2-(2-Cyanoethyl)-*N*-(2,6-dimethylphenyl)benzamide (8a). To a solution of 1a (217 mg, 0.44 mmol) in CHCl₃ (15 mL) was added XyNC (57.2 mg, 0.44 mmol), and the mixture was refluxed for 24 h. A black precipitate of Pd gradually formed. The solvent was removed under vacuum, the residue was extracted with Et₂O (6×5 mL), and the extracts were filtered through Celite. Partial evaporation of the solvents (3 mL) and slow addition of *n*-pentane (30 mL) led to the precipitation of a colorless solid, which was filtered off, washed with *n*-pentane $(5 \times 3 \text{ mL})$, and vacuum-dried to give **8a**. The filtrate was evaporated to dryness, the residue was stirred in *n*-pentane (30 mL) for 1 h, and the resulting suspension was filtered through Celite. Compound **7a** was obtained as a yellow oil after evaporation of the solvent.

7a. Yield: 57 mg, 47%. IR (Nujol, cm⁻¹): ν (NH), 3325; ν (CO), 1707; ν (C==N), 1633. HRMS (ESI+, *m/z*): exact mass calcd for C₁₈H₁₉N₂O [M + H]⁺ requires 279.1492, found 279.1496, error = 1.55 ppm. ¹H NMR (400.9 MHz, CDCl₃): δ 8.19 (dd, ⁴J_{HH} = 1.6 Hz, ³J_{HH} = 7.6 Hz, 1 H, H9), 7.47 (td, ⁴J_{HH} = 1.6 Hz, ³J_{HH} = 7.6 Hz, 1 H, H9), 7.47 (td, ⁴J_{HH} = 1.6 Hz, ³J_{HH} = 7.6 Hz, 1 H, H7), 7.44 (overlapped broad signal, 1 H, NH), 7.42 (td, ⁴J_{HH} = 1.6 Hz, ³J_{HH} = 7.6 Hz, 1 H, H8), 7.23 (m, 1 H, H6), 7.10 (m, 2 H, *m*-H, Xy), 6.97 (m, 1 H, *p*-H, Xy), 3.08–3.05 (m, 2 H, H5), 2.88–2.86 (m, 2 H, H4), 2.14 (s, 6 H, Me). ¹³C{¹H} APT NMR (75.5 MHz, CDCl₃): δ 172.8 (C3), 147.7 (C1), 143.5 (*i*-C, Xy), 139.6 (C5a), 132.5 (C9a), 131.4 (C7), 131.2 (C9), 128.7 (*m*-C, Xy), 128.0 (C6), 127.5 (C8), 124.3 (*p*-C, Xy), 38.0 (C4), 29.4 (C5), 17.9 (Me); *o*-C of Xy not observed.

8a. Yield: 22 mg, 18%. Anal. Calcd for $C_{18}H_{18}N_2O: C, 77.67; H, 6.52; N, 10.06. Found: C, 77.70; H, 6.70; N, 10.10. Mp: 120–122 °C. IR (Nujol, cm⁻¹): <math>\nu$ (NH), 3243; ν (CN), 2245; ν (CO), 1643. HRMS (ESI+, *m/z*): exact mass calcd for $C_{18}H_{19}N_2O$ [M + H]⁺ requires 279.1492, found 279.1496, error = 1.6 ppm. ¹H NMR (400.9 MHz, CDCl₃): δ 7.69 (dd, ⁴J_{HH} = 1.2 Hz, ³J_{HH} = 7.6 Hz, 1 H, H6, Ar), 7.52 (td, ⁴J_{HH} = 1.2 Hz, ³J_{HH} = 7.6 Hz, 1 H, H6, Ar), 7.52 (td, ⁴J_{HH} = 1.2 Hz, ³J_{HH} = 7.6 Hz, 1 H, H4, Ar), 7.44 (m, 1 H, H3, Ar), 7.41 (m, 1 H, H5, Ar), 7.20–7.13 (m, 4 H, NH + Xy), 3.14 (t, ³J_{HH} = 7.2 Hz, 2 H, CH₂CH₂CN), 2.86 (t, ³J_{HH} = 7.2 Hz, 2 H, CH₂CH₂CN), 2.86 (t, ³J_{HH} = 7.2 Hz, 2 H, CH₂CH₂CN), 2.34 (s, 6 H, Me). ¹³C{¹H} APT NMR (75.5 MHz, CDCl₃): δ 167.7 (CO), 137.8 (C2, Ar), 135.5 (C1, Ar), 135.4 (*o*-C, Xy), 133.3 (*i*-C, Xy), 131.4 (C3, Ar), 131.1 (C4, Ar), 128.4 (*m*-C, Xy), 127.8 (*p*-C, Xy), 127.6 (C5, Ar), 127.1 (C6, Ar), 119.4 (CN), 30.0 (CH₂CH₂CN), 19.6 (CH₂CH₂CN), 18.6 (Me).

[Pd{ $\kappa^2 C$, O⁻C(X) ==C(X)C₆H₄(CH₂)₂C(O)NRR'-2}(tmeda)]TfO [NRR' = NH₂, X = Ph (9a), C₆H₄ⁿBu-4 (10a), C₆H₄Br-4 (11a), CO₂Me (12a); NRR' = NHMe, X = Ph (9b); NRR' = NMe₂, X = Ph (9c)]. A mixture of the appropriate complex 1 (0.27 mmol) and AgTfO (74 mg, 0.29 mmol) in acetone (15 mL) was stirred for 30 min. The solvent was removed under vacuum, the residue was extracted with CH₂Cl₂ (6 × 5 mL), and the combined extracts were filtered through anhydrous MgSO₄. The alkyne (0.27 mmol) was then added to the filtrate, and the solution was stirred at room temperature for 3 h (except for the synthesis of 11a, which required 20 h) and then filtered through anhydrous MgSO₄. The filtrate was evaporated to dryness, and the residue was crystallized from CH₂Cl₂/Et₂O (9a−c, 12a), Et₂O/*n*-pentane (10a), or acetone/*n*-pentane (11a). Analytically pure samples of the products were obtained by successive recrystallizations.

9a. Yield: 77%. Anal. Calcd for C30H36F3N3O4PdS: C, 51.61; H, 5.20; N, 6.02; S, 4.59. Found: C, 51.49; H, 5.26; N, 6.01; S, 4.32. Mp: 163–164 °C (dec). IR (Nujol, cm⁻¹): ν (NH), 3395, 3218; ν (CO), 1651. HRMS (ESI+, m/z): exact mass calcd for C₂₉H₃₆N₃OPd [M]⁺ requires 548.1893, found 548.1901, error = 1.46 ppm. HRMS (ESI-, m/z): exact mass calcd for CF₃O₃S [M]⁻ requires 148.9526, found 148.9530, error = 3.20 ppm. ¹H NMR (400.9 MHz, CDCl₃): δ 7.76 (dd, ${}^{4}J_{HH} = 1.2$ Hz, ${}^{3}J_{HH} = 7.6$ Hz, 1 H, Ar), 7.74 (overlapped broad signal, 1 H, NH), 7.53 (br, 1 H, NH), 7.50–7.44 (m, 3 H, Ph + Ar), 7.29 (td, ${}^{4}J_{HH} = 1.2$ Hz, ${}^{3}J_{HH} = 7.6$ Hz, 1 H, Ar), 7.20–7.16 (m, 2 H, Ph), 7.13–7.10 (m, 2 H, Ar + Ph), 7.00–6.94 (m, 3 H, Ph), 6.81–6.78 (m, 2 H, Ph), 3.03 (td, ${}^{3}J_{HH} = 3.2$ Hz, ${}^{2}J_{HH} = 12.8$ Hz, 1 H, CH₂, tmeda), 2.89–2.83 (m, 1 H, CH₂, propanamide), 2.68 (td, ${}^{3}J_{HH} = 3.2$ Hz, ${}^{2}J_{HH}$ = 14.0 Hz, 1 H, CH₂, tmeda), 2.56 (s, 3 H, Me), 2.53–2.40 (m, 2 H, CH₂, propanamide), 2.36 (s, 3 H, Me), 2.38–2.31 (m, 1 H, CH₂, propanamide), 2.27-2.24 (m, 1 H, CH₂, tmeda), 2.15-2.11 (m, 1 H, CH₂, tmeda), 1.97 (s, 3 H, Me), 1.88 (s, 3 H, Me). ¹³C{¹H} APT NMR (75.5 MHz, CDCl₃): δ 184.2 (CO), 145.1 (C, Ar), 143.8 (CPd), 142.6 (C, Ph), 140.34 (PdC=C), 140.28 (C, Ph), 139.8 (C, Ar), 130.6, 130.02 (CH, Ar), 129.96, 129.5, 128.3, 127.40 (CH, Ph), 127.35 (CH, Ar), 125.8 (CH, Ph), 125.7 (CH, Ar), 125.5 (CH, Ph),

65.0, 56.6 (CH₂, tmeda), 53.3, 49.1, 48.9, 44.7 (Me), 37.7, 30.3 (CH₂, propanamide).

9b. Yield: 75%. Anal. Calcd for C₃₁H₃₈F₃N₃O₄PdS: C, 52.28; H, 5.38; N, 5.90; S, 4.50. Found: C, 52.28; H, 5.42; N, 5.93; S, 4.37. Mp: 153–155 °C (dec). IR (Nujol, cm⁻¹): ν (NH), 3278; ν (CO), 1614. HRMS (ESI+, m/z): exact mass calcd for C₃₀H₃₈N₃OPd [M]⁺ requires 562.2050, found 562.2059, error = 1.60 ppm. HRMS (ESI-, m/z): exact mass calcd for CF₃O₃S [M]⁻ requires 148.9526, found 148.9529, error = 2.18 ppm. ¹H NMR (400.9 MHz, CDCl₃): δ 8.48 (br c, ³J_{HH} = 4.8 Hz, 1 H, NH), 7.75 (dd, ${}^{4}J_{HH} = 1.2$ Hz, ${}^{3}J_{HH} = 7.2$ Hz, 1 H, Ar), 7.48 (td, ${}^{4}J_{HH} = 1.2$ Hz, ${}^{3}J_{HH} = 7.2$ Hz, 1 H, Ar), 7.40–7.37 (m, 2 H, Ph), 7.25 (td, ${}^{4}J_{HH} = 1.2$ Hz, ${}^{3}J_{HH} = 7.6$ Hz, 1 H, Ar), 7.20–7.19 (m, 3 H, Ph), 7.09 (dd, ${}^{4}J_{HH} = 1.2$ Hz, ${}^{3}J_{HH} = 7.6$ Hz, 1 H, Ar), 7.03–6.99 (m, 3 H, Ph), 6.87-6.85 (m, 2 H, Ph), 3.29-3.22 (m, 1 H, CH₂, propanamide), 2.98 (td, ${}^{3}J_{HH} = 3.2$ Hz, ${}^{2}J_{HH} = 12.8$ Hz, 1 H, CH₂, tmeda), 2.69 (d, ${}^{3}J_{HH}$ = 4.8 Hz, 3 H, Me, propanamide), 2.68–2.52 (m, 4 H, CH₂, propanamide + tmeda), 2.58 (s, 3 H, Me, tmeda), 2.39-2.35 (m, 1 H, CH₂, tmeda), 2.36 (s, 3 H, Me, tmeda), 2.26-2.21 (m, 1 H, CH₂, tmeda), 1.94 (s, 3 H, Me, tmeda), 1.91 (s, 3 H, Me, tmeda). ${}^{13}C{}^{1}H{}$ APT NMR (75.5 MHz, CDCl₃): δ 180.2 (CO), 144.1 (C, Ar), 143.2 (CPd), 142.3 (C, Ph), 139.0 (PdC=C), 138.42, 138.39 (C, Ph, Ar), 131.2, 129.8 (CH, Ar), 128.8, 128.7, 128.5, 127.7 (CH, Ph), 127.5, 126.18 (CH, Ar), 126.15, 126.0 (CH, Ph), 64.5, 56.8 (CH₂, tmeda), 52.8, 49.4, 48.6, 45.1 (Me, tmeda), 34.5, 31.4 (CH₂, propanamide), 27.6 (Me, propanamide).

9c. Yield: 62%. Anal. Calcd for C₃₂H₄₀F₃N₃O₄PdS: C, 52.93; H, 5.55; N, 5.79; S, 4.42. Found: C, 52.96; H, 5.71; N, 5.79; S, 4.90. Mp: 153–154 °C (dec). IR (Nujol, cm⁻¹): ν (CO), 1592. HRMS (ESI+, m/z): exact mass calcd for $C_{31}H_{40}N_3OPd \ [M]^+$ requires 576.2206, found 576.2217, error = 1.81 ppm. HRMS (ESI-, m/z): exact mass calcd for $CF_{3}O_{3}S$ [M]⁻ requires 148.9526, found 148.9525, error = 0.22 ppm. ¹H NMR (400.9 MHz, CDCl₃): 7.69 (dd, ${}^{4}J_{HH} = 1.6$ Hz, ${}^{3}J_{HH} = 7.6$ Hz, 1 H, Ar), 7.50 (td, ${}^{4}J_{HH} = 1.6$ Hz, ${}^{3}J_{HH} = 7.6$ Hz, 1 H, Ar), 7.44– 7.40 (m, 2 H, Ph), 7.33 (td, ${}^{4}J_{HH} = 1.6$ Hz, ${}^{3}J_{HH} = 7.6$ Hz, 1 H, Ar), 7.22–7.19 (m, 3 H, Ph), 7.11 (dd, ${}^{4}J_{HH} = 1.6$ Hz, ${}^{3}J_{HH} = 7.6$ Hz, 1 H, Ar), 7.06-6.99 (m, 3 H, Ph), 6.86-6.83 (m, 2 H, Ph), 3.59-3.51 (m, 1 H, CH₂, propanamide), 3.23 (s, 3 H, Me, propanamide), 2.95 (s, 3 H, Me, propanamide), 2.95–2.87 (m, 2H, CH₂, propanamide + tmeda), 2.74-2.54 (m, 4 H, CH₂, propanamide + tmeda), 2.51 (s, 3 H, Me, tmeda), 2.44 (s, 3 H, Me, tmeda), 2.41-2.35 (m, 1 H, CH₂, tmeda), 2.08 (s, 3 H, Me, tmeda), 2.06 (s, 3 H, Me, tmeda). ¹³C{¹H} APT NMR (100.8 MHz, CDCl₃): δ 178.6 (CO), 145.2 (CPd), 143.8 (C, Ar), 142.6, 139.3 (C, Ph), 138.9 (PdC=C), 138.0 (C, Ar), 130.6, 130.3 (CH, Ar), 128.95, 128.91, 128.4 (CH, Ph), 127.7 (CH, Ar), 127.6 (CH, Ph), 126.7 (CH, Ar), 126.1, 125.9 (CH, Ph), 64.7, 56.9 (CH2, tmeda), 52.4, 50.1, 48.5, 45.9 (Me, tmeda), 39.4, 37.4 (Me, propanamide), 33.5, 29.4 (CH₂, propanamide).

10a. Yield: 60%. Anal. Calcd for $C_{38}H_{52}F_3N_3O_4PdS\colon$ C, 56.33; H, 6.47; N, 5.19; S, 3.96. Found: C, 56.48; H, 6.77; N, 5.08; S, 4.20. Mp: 104–105 °C. IR (Nujol, cm⁻¹): ν (NH), 3335, 3191; ν (CO), 1649. HRMS (ESI+, m/z): exact mass calcd for C₃₇H₅₂N₃OPd [M]⁺ requires 660.3145, found 660.3154, error = 1.36 ppm. HRMS (ESI-, m/z): exact mass calcd for CF₃O₃S [M]⁻ requires 148.9526, found 148.9529, error = 1.97 ppm. ¹H NMR (400.9 MHz, CDCl₃): δ 7.74 (br, 1 H, NH), 7.73 (m, 1 H, Ar), 7.45–7.40 (m, 3 H, Ph + Ar), 7.29 (m, 1 H, Ar), 7.25 (br, 1 H, NH), 7.13 (m, 1 H, Ar), 7.01 (d, ${}^{3}J_{HH} = 8.0$ Hz, 2 H, Ph), 6.77 (d, ${}^{3}J_{\rm HH}$ = 8.0 Hz, 2 H, Ph), 6.66 (d, ${}^{3}J_{\rm HH}$ = 8.0 Hz, 2 H, Ph), 3.01 (td, ${}^{3}J_{HH} = 3.2$ Hz, ${}^{2}J_{HH} = 12.8$ Hz, 1 H, CH₂, tmeda), 2.80– 2.75 (m, 1 H, CH₂, propanamide), 2.69 (td, ${}^{3}J_{HH} = 2.8$ Hz, ${}^{2}J_{HH} = 13.6$ Hz, 1 H, CH₂, tmeda), 2.56 (s, 3 H, Me, tmeda), 2.53-2.43 (m, 6 H, CH₂, "Bu + propanamide), 2.38 (s, 3 H, Me, tmeda), 2.37-2.31 (m, 1 H, CH₂, propanamide), 2.23-2.20 (m, 1 H, CH₂, tmeda), 2.12-2.08 (m, 1 H, CH₂, tmeda), 1.98 (s, 3 H, Me, tmeda), 1.90 (s, 3 H, Me, tmeda), 1.58-1.44 (m, 4 H, CH₂, "Bu), 1.35-1.21 (m, 4 H, CH₂, ^{*n*}Bu), 0.91 (t, ${}^{3}J_{HH}$ = 7.2 Hz, 3 H, Me), 0.87 (t, ${}^{3}J_{HH}$ = 7.2 Hz, 3 H, Me). ¹³C{¹H} APT NMR (75.5 MHz, CDCl₃): δ 183.8 (CO), 145.1 (C, Ar), 142.9 (CPd), 140.6 (C, C₆H₄ⁿBu-4), 140.0 (C, Ph), 139.7 (C, $C_6H_4^{n}Bu-4$), 139.4 (C, Ar), 139.3 (PdC=C), 137.3 (C, $C_6H_4^{n}Bu-4$), 130.5, 130.2 (CH, Ar), 129.6, 129.1, 128.4, 127.4 (CH, C₆H₄ⁿBu-4), 127.2, 125.7 (CH, Ar), 64.8, 56.6 (CH₂, tmeda), 53.2, 48.9, 48.8, 44.6 (Me, tmeda), 37.1 (CH₂, propanamide), 35.3, 35.1, 33.3, 33.2 (CH₂, "Bu), 30.5 (CH₂, propanamide), 22.2, 22.1 (CH₂, "Bu), 13.92, 13.88 (Me, "Bu).

11a. Yield: 72%. Anal. Calcd for C₃₀H₃₄Br₂F₃N₃O₄PdS: C, 42.10; H, 4.00; N, 4.91; S, 3.75. Found: C, 42.33; H, 4.14; N, 4.86; S, 3.66. Mp: 172–173 °C (dec). IR (Nujol, cm⁻¹): ν (NH), 3378, 3199; ν (CO), 1646. HRMS (ESI+, m/z): exact mass calcd for C₂₉H₃₄N₃OPd [M]⁺ requires 706.0093, found 706.0093, error = 0 ppm. HRMS (ESI-, m/z): exact mass calcd for CF₃O₃S [M]⁻ requires 148.9526, found 148.9526, error = 0 ppm. ¹H NMR (400.9 MHz, CDCl₃): δ 8.19 (br, 1 H, NH), 7.70 (dd, ${}^{4}J_{HH} = 1.2$ Hz, ${}^{3}J_{HH} = 7.6$ Hz, 1 H, Ar), 7.53 (br, 1 H, NH), 7.45-7.41 (m, 3 H, C₆H₄Br-4 + Ar), 7.35-7.30 (m, 3 H, $C_6H_4Br-4 + Ar$), 7.16 (dd, ${}^4J_{HH} = 1.2$ Hz, ${}^3J_{HH} = 7.6$ Hz, 1 H, Ar), 7.11-7.08 (m, 2 H, C₆H₄Br-4), 6.64-6.61 (m, 2 H, C₆H₄Br-4), 3.02 $(td, {}^{3}J_{HH} = 3.2 Hz, {}^{2}J_{HH} = 13.2 Hz, 1 H, CH_{2}, tmeda), 2.82-2.70 (m, 2)$ H, CH₂, propanamide + tmeda), 2.53 (s, 3 H, Me), 2.46-2.44 (m, 2 H, CH₂, propanamide), 2.40 (s, 3 H, Me), 2.35–2.31 (m, 1 H, CH₂, propanamide), 2.27-2.23 (m, 1 H, CH₂, tmeda), 2.12-2.08 (m, 1 H, CH₂, tmeda), 2.01 (s, 3 H, Me), 2.00 (s, 3 H, Me). ¹³C{¹H} APT NMR (75.5 MHz, CDCl₃): δ 184.7 (CO), 145.0 (C, Ar), 143.6 (CPd), 141.6 (C, C_6H_4Br-4), 140.41 (C, Ar), 140.36 (PdC=C), 139.6 (C, C₆H₄Br-4), 131.9, 131.6, 131.4, 130.7 (CH, C₆H₄Br-4), 130.5, 129.7, 127.6, 125.6 (CH, Ar), 120.1, 119.5 (CBr), 65.2, 56.7 (CH₂) tmeda), 53.5, 49.4, 49.0, 44.8 (Me), 38.7, 29.9 (CH₂, propanamide).

12a. Yield: 85%. Anal. Calcd for C₂₂H₃₂F₃N₃O₈PdS: C, 39.92; H, 4.87; N, 6.35; S, 4.84. Found: C, 40.13; H, 5.11; N, 6.37; S, 4.67. Mp: 144–146 °C (dec). IR (Nujol, cm⁻¹): ν (NH), 3385, 3263, 3226; ν (CO), 1712, 1683, 1669. HRMS (ESI+, m/z): exact mass calcd for $C_{21}H_{32}N_3O_5Pd [M]^+$ requires 512.1377, found 512.1385, error = 1.56 ppm. HRMS (ESI-, m/z): exact mass calcd for CF₃O₃S [M]⁻ requires 148.9526, found 148.9528, error = 1.62 ppm. ¹H NMR (400.9 MHz, $CDCl_3$): δ 7.84 (s, 1 H, NH), 7.79 (s, 1 H, NH), 7.46 (dd, ${}^{4}J_{HH} = 1.2$ Hz, ${}^{3}J_{HH} = 7.6$ Hz, 1 H, Ar), 7.38 (td, ${}^{4}J_{HH} = 1.2$ Hz, ${}^{3}J_{HH} = 7.6$ Hz, 1 H, Ar), 7.33 (td, ${}^{4}J_{HH} = 1.2$ Hz, ${}^{3}J_{HH} = 7.6$ Hz, 1 H, Ar), 7.21 (m, 1 H, Ar), 3.89 (s, 3 H, CO₂Me), 3.61 (s, 3 H, CO₂Me), 3.07–2.78 (m, 4 H, CH₂, tmeda + propanamide), 2.90 (s, 3 H, Me, tmeda), 2.86 (s, 3 H, Me, tmeda), 2.55-2.48 (m, 1 H, CH₂, propanamide), 2.34 (s, 3 H, Me, tmeda), 2.35-2.23 (m, 2 H, CH₂, tmeda + propanamide), 2.20-2.17 (m, 1 H, CH₂, tmeda), 2.03 (s, 3 H, Me, tmeda). ¹³C{¹H} APT NMR (75.5 MHz, CDCl₃): δ 184.2 (CONH₂), 172.9, 162.3 (CO₂Me), 159.6 (CPd), 140.6, 139.9 (C, Ar), 135.2 (PdC=C), 129.7, 128.9, 128.1, 126.3 (CH, Ar), 65.5, 57.7 (CH₂, tmeda), 55.0 (Me, tmeda), 52.11, 52.04 (CO₂Me), 49.2, 48.6, 45.0 (Me, tmeda), 39.3, 31.1 (CH₂, propanamide).

Synthesis of $[Pd{\eta^3-C_6H_4(C_4Et_4)(CH_2)_2C(O)NH_2}(tmeda)]TfO$ (13). To a solution of 1a (262 mg, 0.53 mmol) in acetone (15 mL) was added AgTfO (136 mg, 0.53 mmol), and the resulting suspension was stirred for 30 min. The solvent was removed under vacuum, the residue was extracted with CH_2Cl_2 (6 × 5 mL), and the combined extracts were filtered through anhydrous MgSO₄. 3-Hexyne (180 µL, 1.57 mmol) was then added to the filtrate, and the mixture was stirred for 15 h and filtered through anhydrous MgSO₄. Partial evaporation of the filtrate (5 mL) and addition of *n*-pentane (30 mL) gave a yellowish orange precipitate, which was collected by filtration and recrystallized from CH₂Cl₂/Et₂O to give 13 as a yellow solid. Yield: 291 mg, 81%. Anal. Calcd for C₂₈H₄₆F₃N₃O₄PdS: C, 49.16; H, 6.78; N, 6.14; S, 4.69. Found: C, 48.71; H, 6.79; N, 6.05; S, 4.50. Mp: 122-123 °C (dec). IR (Nujol, cm⁻¹): ν (NH), 3353, 3160; ν (CO), 1684. HRMS (ESI+, m/ z): exact mass calcd for C₂₇H₄₆N₃OPd [M]⁺ requires 534.2676, found 534.2697, error = 3.93 ppm. HRMS (ESI-, m/z): exact mass calcd for CF₃O₃S [M]⁻ requires 148.9526, found 148.9529, error = 2.05 ppm. ¹H NMR (400.9 MHz, CDCl₃): δ 6.70 (br, 1 H, NH), 6.10 (d, ³J_{HH} = 6.0 Hz, H9), 6.01 (dd, ${}^{3}J_{HH} = 6.4$ Hz, ${}^{3}J_{HH} = 6.8$ Hz, H7), 5.24 (br, 1 H, NH), 4.69-4.64 (m, 2 H, H6, H8), 2.91-2.63 (m, 8 H, CH₂CH₃ + CH₂, tmeda), 2.78 (s, 12 H, Me, tmeda), 2.39–2.23 (m, 6 H, CH₂CH₃ + CH₂, propanamide), 2.01-1.79 (m, 1 H, CH₂CH₃), 1.78-1.62 (m, 2 H, CH₂CH₃ + CH₂, propanamide), 1.56–1.47 (m, 1 H, CH₂, propanamide), 1.16 (t, ${}^{3}J_{HH} = 7.6$ Hz, 3 H, CH₂CH₃), 1.11–1.06 (m, 6 H, CH₂CH₃), 0.98 (t, ${}^{3}J_{HH} = 7.6$ Hz, 3 H, CH₂CH₃). ${}^{13}C{}^{1}H$ APT NMR (100.8 MHz, CDCl₃): δ 174.5 (CO), 147.6, 146.3, 139.8, 138.2

(C1-4), 129.4 (C10), 114.2 (C9), 107.8 (C7), 103.1 (C6), 70.7 (C5), 64.6 (C8), 60.2 (CH_2, tmeda) , 51.0 (br, Me, tmeda), 31.7, 25.2 $(CH_2, \text{propanamide})$, 22.4, 19.12, 19.09, 18.3 (CH_2CH_3) , 15.3, 15.1, 14.9, 14.5 (CH_2CH_3) .

Synthesis of (Z)-6,7-Diphenyl-1,2-dihydro-4*H*-benzo[*e*]azonine-3,5-dione (14), (Z)-6,7-Bis(4-butylphenyl)-1,2-dihydro-4*H*-benzo[*e*]azonine-3,5-dione (15), and (Z)-6,7-Bis(4-bromophenyl)-1,2-dihydro-4*H*-benzo[*e*]azonine-3,5-dione (16). A solution of the corresponding complex 9a, 10a, or 11a (0.30 mmol) in CHCl₃ (15 mL) was stirred under a CO atmosphere (1.4 bar) at 50 °C for 15 h, whereupon a black precipitate of Pd gradually formed. The suspension was filtered through anhydrous MgSO₄, and the solvent was removed under reduced pressure. The residue was purified by flash chromatography on silica gel, using a 3:1 EtOAc/*n*-hexane mixture as eluent [$R_f = 0.8-0.9$ (14), 0.7–0.8 (15), 0.8 (16)]. The compounds were isolated as colorless solids (14 and 16) or as a yellow oil (15) after evaporation of the solvents.

14. Yield: 52%. Mp: 202–203 °C. IR (Nujol, cm⁻¹): ν (NH), 3224; ν (C=O), 1685. HRMS (ESI+, m/z): exact mass calcd for C₂₄H₂₀NO₂ [M + H]⁺ requires 354.1489, found 354.1493, error = 1.19 ppm. ¹H NMR (400.9 MHz, CDCl₃): δ 7.68 (br, 1 H, NH), 7.36–7.08 (m, 14 H, H8–11 + Ph), 3.99–3.91 (m, 1 H, H2), 3.25–3.19 (m, 1 H, H1), 3.07–2.99 (m, 1 H, H1), 2.87–2.82 (m, 1 H, H2). ¹³C{¹H} APT NMR (75.5 MHz, CDCl₃): δ 172.4 (C3), 169.6 (C5), 141.7 (C7), 140.1 (C7a), 137.0 (C, Ph), 135.6 (C11a), 134.6 (C, Ph), 134.1 (C6), 131.2 (C11), 129.8 (CH, Ph), 129.4 (CH, Ph + C8), 128.9 (CH, Ph), 128.8 (C10), 128.6 (CH, Ph), 128.32 (CH, Ph), 128.28 (CH, Ph), 127.7 (C9), 34.4 (C2), 31.2 (C1).

15. Yield: 46%. IR (CH₂Cl₂, cm⁻¹): ν(C=O), 1701, 1681. HRMS (ESI+, m/z): exact mass calcd for $C_{32}H_{36}NO_2$ [M + H]⁺ requires 466.2741, found 466.2746, error = 1.15 ppm. ¹H NMR (400.9 MHz, CDCl₃): δ 7.59 (br, 1 H, NH), 7.31–7.21 (m, 5 H, H8–10 + H2 and H6 of C₆H₄"Bu-4), 7.15–7.13 (m, 1 H, H11), 7.11–7.07 (m, 2 H, H3 and H5 of C₆H₄ⁿBu-4), 7.01-6.98 (m, 2 H, H2 and H6 of C₆H₄ⁿBu-4), 6.96–6.94 (m, 2 H, H3 and H5 of C₆H₄ⁿBu-4), 3.97–3.91 (m, 1 H, H2), 3.23-3.17 (m, 1 H, H1), 3.04-2.96 (m, 1 H, H1), 2.83-2.78 (m, 1 H, H2), 2.59 (t, ${}^{3}J_{HH} = 8.0$ Hz, 2 H, CH₂, ${}^{"}Bu$), 2.52 (t, ${}^{3}J_{HH} = 8.0$ Hz, 2 H, CH₂, ${}^{"}Bu$), 1.59–1.49 (m, 4 H, CH₂, ${}^{"}Bu$), 1.39–1.25 (m, 4 H, CH₂, ^{*n*}Bu), 0.92 (t, ³ $J_{\rm HH}$ = 7.2 Hz, 3 H, Me), 0.89 (t, ³ $J_{\rm HH}$ = 7.2 Hz, 3 H, Me). ¹³C{¹H} APT NMR (100.8 MHz, CDCl₃): δ 172.6 (C3), 170.0 (C5), 143.4, 143.3 (C, C₆H₄ⁿBu-4), 141.0 (C7), 140.5 (C7a), 135.7 (C11a), 134.3 (C, C₆H₄"Bu-4), 133.4 (C6), 131.9 (C, C₆H₄"Bu-4), 131.1 (C11), 129.7 (CH, C₆H₄"Bu-4), 129.5 (C8), 129.2, 128.9 (CH, C₆H₄ⁿBu-4), 128.7 (C10), 128.2 (CH, C₆H₄ⁿBu-4), 127.7 (C9), 35.4, 35.3 (CH₂, "Bu), 34.4 (C2), 33.3, 33.2 (CH₂, "Bu), 31.2 (C1), 22.3 (CH₂, ⁿBu), 13.91, 13.89 (Me).

16. Yield: 72%. Anal. Calcd for C₂₄H₁₇Br₂NO₂: C, 56.39; H, 3.35; N, 2.74. Found: C, 56.31; H, 3.38; N, 2.82. Mp: 155–157 °C. IR (Nujol, cm⁻¹): ν (NH), 3200; ν (C=O), 1702, 1682. HRMS (ESI+, *m/z*): exact mass calcd for C₂₄H₁₈Br₂NO₂ [M + H]⁺ requires 511.968, found 511.969, error = 2.01 ppm. ¹H NMR (400.9 MHz, CDCl₃): δ 7.64 (br, 1 H, NH), 7.47–7.43 (m, 2 H, C₆H₄Br-4), 7.34–7.28 (m, 4 H, H9, H10 + C₆H₄Br-4), 7.24–7.21 (m, 2 H, C₆H₄Br-4), 7.20–7.16 (m, 2 H, H8, H11), 6.97–6.93 (m, 2 H, C₆H₄Br-4), 3.81–3.73 (m, 1 H, H2), 3.21–3.15 (m, 1 H, H1), 3.09–3.01 (m, 1 H, H1), 2.87–2.82 (m, 1 H, H2). ¹³C{¹H} APT NMR (100.8 MHz, CDCl₃): δ 172.0 (C3), 168.8 (C5), 141.1 (C7), 139.4 (C7a), 135.7 (C, C₆H₄Br-4), 135.4 (C11a), 133.6 (C6), 133.1 (C, C₆H₄Br-4), 132.4, 131.8 (CH, C₆H₄Br-4), 131.4 (C11), 131.3, 130.9 (CH, C₆H₄Br-4), 129.3 (C8), 129.2 (C10), 128.0 (C9), 123.2, 123.0 (CBr), 34.5 (C2), 31.1 (C1).

ASSOCIATED CONTENT

S Supporting Information

Experimental procedures and spectroscopic and analytical data for 3-(2-bromophenyl)propanamide, 3-(2-bromophenyl)-*N*methylpropanamide, 3-(2-bromophenyl)-*N*,*N*-dimethylpropanamide, and their iodo analogues. ¹H and ¹³C{¹H} NMR spectra of **2a**, **2c**, **7a**, **14** and **15**. Crystallographic data in CIF format for **1b**, **3a**, **8a**, **9a**, **13**·CH₂Cl₂ and **14**. Table of

Organometallics

crystallographic data. Packing diagrams for 13 and 14. This material is available free of charge via the Internet at http:// pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author

*E-mail: jvs1@um.es (J.V.), p.jones@tu-bs.de (P.G.J.).

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We thank Ministerio de Educación y Ciencia (Spain), FEDER (CTQ2007-60808/BQU, CTQ2011-24016) and Fundación Séneca (04539/GERM/06) for financial support and a grant to R.F.P.

REFERENCES

(1) Dyker, G. Chem. Ber./Recl. 1997, 130, 1567-1578.

(2) Oestreich, M.; Dennison, P. R.; Kodanko, J. J.; Overman, L. E. Angew. Chem., Int. Ed. 2001, 40, 1439–1442. Burke, B. J.; Overman, L. E. J. Am. Chem. Soc. 2004, 126, 16820–16833. Beccalli, E. M.; Borsini, E.; Brenna, S.; Galli, S.; Rigamonti, M.; Broggini, G. Chem.—Eur. J. 2010, 16, 1670–1678. Rousseaux, S.; Davi, M.; Sofack-Kreutzer, J.; Pierre, C.; Kefalidis, C. E.; Clot, E.; Fagnou, K.; Baudoin, O. J. Am. Chem. Soc. 2010, 132, 10706–10716. Donati, L.; Leproux, P.; Prost, E.; Michel, S.; Tillequin, F.; Gandon, V.; Poree, F.-H. Chem.—Eur. J. 2011, 17, 12809–12819. Chai, D. I.; Thansandote, P.; Lautens, M. Chem.—Eur. J. 2011, 17, 8175–8188. Yao, B.; Wang, Q.; Zhu, J. Angew. Chem., Int. Ed. 2012, 51, 5170–5174.

(3) Dupont, J.; Consorti, C. S.; Spencer, J. Chem. Rev. 2005, 105, 2527-2571.

(4) Zeni, G.; Larock, R. C. Chem. Rev. **2006**, 106, 4644–4680. Majumdar, K. C.; Samanta, S.; Sinha, B. Synthesis **2012**, 44, 817–847.

(5) Wu, X. F.; Neumann, H.; Beller, M. Chem. Rev. 2013, 113, 1–35.
(6) Larock, R. C.; Tu, C.; Pace, P. J. Org. Chem. 1998, 63, 6859–6866. Yet, L. Chem. Rev. 2000, 100, 2963–3007. Hu, T.; Corey, E. J. Org. Lett. 2002, 4, 2441–2443. Ohno, H.; Hamaguchi, H.; Ohata, M.; Kosaka, S.; Tanaka, T. J. Am. Chem. Soc. 2004, 126, 8744–8754. Trost, B. M.; Ameriks, M. K. Org. Lett. 2004, 6, 1745–1748. Jiang, X. P.; Yang, Q.; Yu, Y. H.; Fu, C. L.; Ma, S. M. Chem.—Eur. J. 2009, 15, 7283–7286. Majumdar, K. C.; Chattopadhyay, B. Curr. Org. Chem. 2009, 13, 731–757. Majumdar, K. C. RSC Adv. 2011, 1, 1152–1170.
(7) Illuminati, G.; Mandolini, L. Acc. Chem. Res. 1981, 14, 95–102. Evans, P. A.; Holmes, B. Tetrahedron 1991, 47, 9131–9166. Maier, M. E. Angew. Chem. Int. Ed. 2000, 39, 2073–2077. Ma, S.; Gu, Z. J. Am. Chem. Soc. 2006, 128, 4942–4943.

(8) Palladacycles. Synthesis, Characterization and Applications; Dupont, J., Pfeffer, M., Eds.; Wiley-VCH: Weinheim, 2008.

(9) Stephen, A.; Hashmi, K.; Nass, A. R.; Bats, J. W.; Bolte, M. Angew. Chem., Int. Ed. **1999**, 38, 3370–3373. Beletskaya, I. P.; Cheprakov, A. V. J. Organomet. Chem. **2004**, 689, 4055–4082. Lee, H. M.; Lu, C. Y.; Chen, C. Y.; Chen, W. L.; Lin, H. C.; Chiu, P. L.; Cheng, P. Y. Tetrahedron **2004**, 60, 5807–5825.

(10) Bahsoun, A.; Dehand, J.; Pfeffer, M.; Zinsius, M.; Bouaoud, S.-E.; Le Borgne, G. J. Chem. Soc., Dalton Trans. **1979**, 547–556. Dupont, J.; Pfeffer, M. J. Organomet. Chem. **1987**, 321, C13–C16. Maassarani, F.; Pfeffer, M.; Le, B. G. Organometallics **1987**, 6, 2029–2043. Beydoun, N.; Pfeffer, M.; DeCian, A.; Fischer, J. Organometallics **1991**, 10, 3693–3697.

(11) Dehand, J.; Mutet, C.; Pfeffer, M. J. Organomet. Chem. 1981, 209, 255–270. Arlen, C.; Pfeffer, M.; Bars, O.; Grandjean, D. J. Chem. Soc., Dalton Trans. 1983, 1535–1544. Ossor, H.; Pfeffer, M.; Jastrzebski, J. T. B. H.; Stam, C. H. Inorg. Chem. 1987, 26, 1169–1171. Pereira, M. T.; Pfeffer, M.; Rotteveel, M. A. J. Organomet. Chem. 1989, 375, 139–145. Chicote, M.-T.; Vicente-Hernández, I.; Jones, P. G.; Vicente, J. Organometallics 2012, 31, 6252–6261.

(12) Spencer, J.; Pfeffer, M.; Kyritsakas, N.; Fischer, J. Organometallics 1995, 14, 2214–2224.

(13) Spencer, J.; Pfeffer, M.; DeCian, A.; Fischer, J. J. Org. Chem. 1995, 60, 1005–1012.

(14) Vicente, J.; Abad, J.-A.; Shaw, K. F.; Gil-Rubio, J.; Ramírez de Arellano, M. C.; Jones, P. G. Organometallics **1997**, *16*, 4557–4566.

(15) Benito, M.; López, C.; Morvan, X.; Solans, X.; Font-Bardia, M. Dalton Trans. 2000, 4470–4478.

(16) Gül, N.; Nelson, J. H.; Willis, A. C.; Rae, A. D. Organometallics 2002, 21, 2041–2048. Kelly, A. E.; MacGregor, S. A.; Willis, A. C.; Nelson, J. H.; Wenger, E. Inorg. Chim. Acta 2003, 352, 79–97.

(17) Vicente, J.; Saura-Llamas, I.; Turpín, J.; Bautista, D.; Ramírez de Arellano, M. C.; Jones, P. G. Organometallics 2009, 28, 4175-4195.

(18) Maassarani, F.; Pfeffer, M.; Le, B. G. Organometallics 1987, 6, 2043-2053.

(19) Dupont, J.; Pfeffer, M.; Theurel, L.; Rotteveel, M. A.; De, C. A.; Fischer, J. New J. Chem. **1991**, 15, 551–558.

(20) Vicente, J.; Abad, J. A.; López-Serrano, J.; Jones, P. G.; Nájera, C.; Botella-Segura, L. *Organometallics* **2005**, *24*, 5044–5057.

(21) Albert, J.; Granell, J.; Luque, A.; Font-Bardia, M.; Solans, X. *Polyhedron* **2006**, 25, 793–800. García-López, J.-A.; Oliva-Madrid, M.-J.; Saura-Llamas, I.; Bautista, D.; Vicente, J. *Chem. Commun.* **2012**, 48, 6744–6746.

(22) Frutos-Pedreño, R.; González-Herrero, P.; Vicente, J.; Jones, P. G. Organometallics **2012**, *31*, 3361–3372.

(23) Tao, W.; Silverberg, L. J.; Rheingold, A. L.; Heck, R. F. Organometallics 1989, 8, 2550–2559. Pfeffer, M.; Rotteveel, M. A.; Le, B. G.; Fischer, J. J. Org. Chem. 1992, 57, 2147–2154. Vicente, J.; Saura-Llamas, I.; Ramírez de Arellano, M. C. J. Chem. Soc., Dalton Trans. 1995, 2529–2533. Bosque, R.; Benito, M.; López, C. New J. Chem. 2001, 25, 827–833.

(24) Vicente, J.; Saura-Llamas, I.; Turpín, J.; Ramírez de Arellano, M. C.; Jones, P. G. *Organometallics* **1999**, *18*, 2683–2693.

(25) Vicente, J.; Saura-Llamas, I.; García-López, J. A.; Bautista, D. Organometallics **2010**, *29*, 4320–4338.

(26) García-López, J.-A.; Oliva-Madrid, M.-J.; Saura-Llamas, I.; Bautista, D.; Vicente, J. Organometallics **2012**, *31*, 6351–6364.

(27) Vicente, J.; Saura-Llamas, I.; García-López, J. A.; Bautista, D. Organometallics 2009, 28, 448-464.

(28) Oliva-Madrid, M.-J.; García-López, J.-A.; Saura-Llamas, I.; Bautista, D.; Vicente, J. Organometallics **2012**, *31*, 3647–3660.

(29) Vicente, J.; Saura-Llamas, I.; García-López, J. A.; Calmuschi-Cula, B.; Bautista, D. Organometallics **2007**, *26*, 2768–2776.

(30) Vicente, J.; González-Herrero, P.; Frutos-Pedreño, R.; Chicote,

M. T.; Jones, P. G.; Bautista, D. Organometallics **2011**, 30, 1079–1093. (31) Büch, H. M.; Krüger, C. Acta Crystallogr., Sect. C: Cryst. Struct.

Commun. 1984, 40, 28–30. Marshall, C.; Ward, M. F.; Harrison, W. T. A. *Tetrahedron Lett.* 2004, 45, 5703–5706.

(32) Yamamoto, T.; Sano, K.; Osakada, K.; Komiya, S.; Yamamoto, A.; Kushi, Y.; Tada, T. *Organometallics* **1990**, *9*, 2396–2403.

(33) Monteiro, A. L.; Davis, W. M. J. Braz. Chem. Soc. 2004, 15, 83-95.

(34) Dupont, J.; Pfeffer, M.; Daran, J. C.; Jeannin, Y. Organometallics 1987, 6, 899-901.

(35) Dupont, J.; Pfeffer, M. J. Chem. Soc., Dalton Trans. **1990**, 3193– 3198. Kim, Y. J.; Song, S. W.; Lee, S. C.; Lee, S. W.; Osakada, K.; Yamamoto, T. J. Chem. Soc., Dalton Trans. **1998**, 1775–1779. Lindsell, W. E.; Palmer, D. D.; Preston, P. N.; Rosair, G. M.; Jones, R. V. H.; Whitton, A. J. Organometallics **2005**, 24, 1119–1133. Meana, I.; Albéniz, A. C.; Espinet, P. Organometallics **2008**, 27, 4193–4198.

(36) Vicente, J.; Abad, J. A.; Frankland, A. D.; Ramírez de Arellano, M. C. *Chem.—Eur. J.* **1999**, *5*, 3066–3075.

(37) Vicente, J.; Abad, J.-A.; Förtsch, W.; López-Sáez, M.-J.; Jones, P. G. Organometallics **2004**, 23, 4414–4429.

(38) Mori, M.; Chiba, K.; Ban, Y. J. Org. Chem. **1978**, 43, 1684–1687. Moser, W. R.; Wang, A. W.; Kildahl, N. K. J. Am. Chem. Soc. **1988**, 110, 2816–2820. Negishi, E.-i.; Zhang, Y.; Shimoyama, I.; Wu, G. J. Am. Chem. Soc. **1989**, 111, 8018–8020. Yamamoto, A. Bull. Chem. Soc. Jpn. **1995**, 68, 433–446. Barnard, C. F. J. Organometallics **2008**, 27, 5402– 5422. Wu, X.-F.; Neumann, H.; Spannenberg, A.; Schulz, T.; Jiao, H.; Beller, M. J. Am. Chem. Soc. **2010**, 132, 14596–14602.

(39) Walker, G. N. J. Org. Chem. **1972**, 37, 3955–3958. Kamei, K.; Maeda, N.; Nomura, K.; Shibata, M.; Katsuragi-Ogino, R.; Koyama, M.; Nakajima, M.; Inoue, T.; Ohno, T.; Tatsuoka, T. *Bioorg. Med. Chem.* **2006**, *14*, 1978–1992.

(40) Lebrun, S.; Couture, A.; Deniau, E.; Grandclaudon, P. Synthesis 2012, 44, 1410–1416.

(41) Tollari, S.; Cenini, S.; Tunice, C.; Palmisano, G. Inorg. Chim. Acta **1998**, 272, 18–23. Tollari, S.; Demartin, F.; Cenini, S.; Palmisano, G.; Raimondi, P. J. Organomet. Chem. **1997**, 527, 93–102.

(42) Thompson, J. M.; Heck, R. F. J. Org. Chem. 1975, 40, 2667–2674.

(43) O'Sullivan, R. D.; Parkins, A. W. J. Chem. Soc., Chem. Commun. 1984, 1165–1166.

(44) Barr, N.; Bartley, J. P.; Clark, P. W.; Dunstan, P.; Dyke, S. F. J. Organomet. Chem. **1986**, 302, 117–126.

(45) Yamamoto, Y.; Yamazaki, H. Inorg. Chim. Acta 1980, 41, 229–232. Usón, R.; Forniés, J.; Espinet, P.; Lalinde, E. J. Organomet. Chem. 1983, 254, 371–379. Zografidis, A.; Polborn, K.; Beck, W.; Markies, B. A.; van Koten, G. Z. Naturforsch., B. 1994, 49, 1494–1498. Delis, J. G. P.; Aubel, P. G.; Vrieze, K.; van Leeuwen, P. W. N. M.; Veldman, N.; Spek, A. L.; van Neer, F. J. R. Organometallics 1997, 16, 2948–2957. (46) Vicente, J.; Abad, J. A.; Förtsch, W.; Jones, P. G.; Fischer, A. K. Organometallics 2001, 20, 2704–2715. Vicente, J.; Abad, J. A.; Frankland, A. D.; López-Serrano, J.; Ramírez de Arellano, M. C.; Jones, P. G. Organometallics 2002, 21, 272–282. Vicente, J.; Abad, J. A.; Martínez-Viviente, E.; Jones, P. G. Organometallics 2002, 21, 4454–4467.

(47) Yamamoto, Y.; Yamazaki, H. Synthesis **1976**, 750–751. Gehrig, K.; Klaus, A. J.; Rys, P. Helv. Chim. Acta **1983**, 66, 2603–2607. Albinati, A.; Pregosin, P. S.; Ruedi, R. Helv. Chim. Acta **1985**, 68, 2046–2061. Onitsuka, K.; Yamamoto, M.; Suzuki, S.; Takahashi, S. Organometallics **2002**, 21, 581–583. Vicente, J.; Saura-Llamas, I.; Grünwald, C.; Alcaraz, C.; Jones, P. G.; Bautista, D. Organometallics **2002**, 21, 3587–3595.

(48) Onitsuka, K.; Suzuki, S.; Takahashi, S. *Tetrahedron Lett.* **2002**, 43, 6197–6199. Saluste, C. G.; Whitby, R. J.; Furber, M. *Angew. Chem., Int. Ed.* **2000**, *39*, 4156–4158. Curran, D. P.; Du, W. *Org. Lett.* **2002**, *4*, 3215–3218.

(49) Vicente, J.; Chicote, M. T.; Martínez-Martínez, A. J.; Jones, P. G.; Bautista, D. Organometallics **2008**, 27, 3254–3271. Vicente, J.; Abad, J. A.; López-Nicolás, R-M.; Jones, P. G. Organometallics **2011**, 30, 4983–4998.

(50) Dupont, J.; Pfeffer, M.; Rotteveel, M. A.; De, C. A.; Fischer, J. *Organometallics* **1989**, *8*, 1116–1118. Vicente, J.; Abad, J.-A.; Gil-Rubio, I.; Jones, P. G. *Organometallics* **1995**, *14*, 2677–2688.

(51) Pfeffer, M. Pure Appl. Chem. 1992, 64, 335-342.

(52) Chip, G. K.; Lynch, T. R. J. Chem. Soc., Chem. Commun. 1973, 641–642. Chip, G. K.; Lynch, T. R. Can. J. Chem. 1974, 52, 2249–2254.

(53) Minisci, F.; Punta, C.; Recupero, F.; Fontana, F.; Pedulli, G. F. J. Org. Chem. 2002, 67, 2671–2676. Nicolaou, K. C.; Mathison, C. J. N. Angew. Chem., Int. Ed. 2005, 44, 5992–5997.

(54) Vicente, J.; Abad, J. A.; Fernández de Bobadilla, R.; Jones, P. G.; Ramírez de Arellano, M. C. Organometallics **1996**, *15*, 24–34. Vicente, J.; Abad, J.; López-Serrano, J.; Jones, P. G. Organometallics **2004**, *23*, 4711–4722. Vicente, J.; Abad, J. A.; Hernández-Mata, F. S.; Rink, B.; Jones, P. G.; Ramírez de Arellano, M. C. Organometallics **2004**, *23*, 1292–1304.

(55) Haas, K.; Ehrenstorfer-Schäfers, E.-M.; Polborn, K.; Beck, W. *Eur. J. Inorg. Chem.* **1999**, 465–469. Behrens, H.; Fröhlich, R.; Würthwein, E.-U. *Eur. J. Org. Chem.* **2005**, 3891–3899. Zaitsev, V. G.; Shabashov, D.; Daugulis, O. *J. Am. Chem. Soc.* **2005**, *127*, 13154– 13155. Liao, C.-Y.; Chan, K.-T.; Zeng, J.-Y.; Hu, C.-H.; Tu, C.-Y.; Lee, H. M. Organometallics **2007**, *26*, 1692–1702.

(56) Reddy, K. R.; Surekha, K.; Lee, G.-H.; Peng, S.-M.; Liu, S.-T. Organometallics **2001**, 20, 5557–5563.

(57) Hegedus, L. S.; Åkermark, B.; Olsen, D. J.; Anderson, O. P.;
Zetterberg, K. J. Am. Chem. Soc. 1982, 104, 697–704. Murrall, N. W.;
Welch, A. J. J. Organomet. Chem. 1986, 301, 109–130. Barbaro, P.;
Pregosin, P. S.; Salzmann, R.; Albinati, A.; Kunz, R. Organometallics
1995, 14, 5160–5170. Vicente, J.; Abad, J. A.; López-Sáez, M. J.; Jones,
P. G. Organometallics 2010, 29, 409–416.

(58) Hernández, R.; Melián, D.; Prangé, T.; Suárez, E. *Heterocycles* **1995**, *41*, 439–454.

(59) Takahashi, Y.; Ito, T.; Sakai, S.; Ishii, Y. J. Chem. Soc., Chem. Commun. 1970, 1065–1066.

(60) Klapars, A.; Antilla, J. C.; Huang, X. H.; Buchwald, S. L. J. Am. Chem. Soc. 2001, 123, 7727–7729.

(61) Sheldrick, G. M. Acta Crystallogr., Sect. A: Found. Crystallogr. 2008, 64, 112–122.